

CURRICULUM VITAE

Ronald Curtis Kennedy

Birthdate: November 3, 1954

Birthplace: Farmington, Connecticut

Education: Field	Degree	Year	Major
Rutgers College, New Brunswick, NJ	B.A.	1976	Microbiology
University of Hawaii, Honolulu, HI	M.S.	1977	Microbiology (Immunogenetics)
University of Hawaii, Honolulu, HI	Ph.D.	1981	Microbiology (Immunochemistry)

Present Positions:

- 2001-Present Professor and Chairman, Department of Microbiology and Immunology, Texas Tech University Health Sciences Center, Lubbock, Texas
- 1994-Present Adjunct Scientist, Departments of Virology and Immunology and Physiology and Medicine, Southwest Foundation for Biomedical Research, San Antonio, Texas

Previous Positions:

- 1998-2001 Director, NCRR/NIH Baboon Research Resource, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma.
- 1994-2001 Professor, Department of Microbiology and Immunology, College of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma
- 1997-2001 Professor, Department of Obstetrics and Gynecology, Division of Maternal-Fetal Medicine, College of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma
- 1993-1996 Adjunct Professor, Department of Pediatrics, University of Texas Health Science Center, San Antonio, Texas
- 1989-1994 Scientist, Department of Virology and Immunology, Southwest Foundation for Biomedical Research, San Antonio, Texas
- 1990-1994 Adjunct Professor, Department of Microbiology, University of Texas Health Science Center, San Antonio, Texas
- 1991-1994 Director, NIAID/NIH Center for AIDS Research, Southwest Foundation for Biomedical Research, San Antonio, Texas
- 1987-1990 Adjunct Associate Professor, Department of Microbiology, University of Texas Health Science Center, San Antonio, Texas
- 1986-1989 Associate Scientist, Department of Virology and Immunology, Southwest Foundation for Biomedical Research, San Antonio, Texas
- 1985-1987 Adjunct Assistant Professor, Department of Microbiology, University of Texas Health Science Center, San Antonio, Texas
- 1984-1986 Assistant Scientist, Department of Virology and Immunology, Southwest Foundation for Biomedical Research, San Antonio, Texas
- 1983-1984 Assistant Professor, Department of Virology and Epidemiology, Baylor College of Medicine, Houston, Texas
- 1981-1983 Postdoctoral Trainee, Department of Virology and Epidemiology, Baylor College of Medicine, Houston, Texas
- 1981 Instructor, Department of Microbiology, University of Hawaii, Honolulu, Hawaii
- 1979-1980 National Institutes of Health Predoctoral fellow, University of Hawaii, Honolulu, Hawaii
- 1976-1979 Teaching Assistant, Department of Microbiology, University of Hawaii, Honolulu, Hawaii

Fellowships:

- 1981-1983 NIH Postdoctoral Fellowship, Department of Virology and Epidemiology, Baylor College of Medicine, Houston, Texas (J.S. Butel, P.I.)

Fellowships: (continued)

1984-1987 NIAID New Investigator Research Award
 1987-1988 Grant from the American Foundation for AIDS Research (AmFAR)

Honors and Awards:

1989-1993 Who's Who, San Antonio Business Journal
 1991-1993 Chairman, San Antonio City Council AIDS/HIV Commission
 1990-1994 Member, San Antonio City Council AIDS/HIV Commission
 1991-1994 Member, American Cancer Society Advisory Board, Texas Division
 1991-1994 Member, San Antonio City Council HIV Education Committee
 1991-1994 Member, San Antonio City Council AIDS/HIV Executive Committee
 1992-1994 Advisory Board, San Antonio AIDS Foundation, Walk for Life
 1993-1994 Advisor, Metropolitan Health District, Bexar County, Texas, San Antonio-Kumamoto City, Japan, Sister City AIDS Cooperative Agreement
 1993-1994 Advisor, City of San Antonio, San Antonio-Kumamoto City, Japan, Sister City AIDS Cooperative Agreement
 1994 Delegate, City of San Antonio, Kumamoto City International Exchange Center Opening Ceremony
 1994-Present Honorary Director, Kumamoto City Hospital, Kumamoto City, Japan
 1996 Citation for Outstanding Service to the Community, City of San Antonio, Texas
 1998 University of Oklahoma Health Sciences Center Provost Senior Research Award

Professional Societies:

American Society for Microbiology
 American Association of Immunology
 American Association for the Advancement of Science
 International AIDS Society
 American Peptide Society
 International Society for Antiviral Research
 American Association for Cancer Research
 American Society for Virology
 International Association of Retroviruses
 Association of U.S.A. Microbiology and Immunology Chairs

Professional Scientific Activities:

1985-1986 Representative, American Society for Microbiology, Texas Branch
 1987-1988 Correspondent to Institutes of Medicine and National Academy of Sciences Committee on Confronting AIDS
 1987-1988 Executive Committee, Sixth Annual Nonhuman Primate Models for AIDS, San Antonio, Texas
 1989-1990 Member, Scientific Program Committee, Sixth International Conference on AIDS, San Francisco, California, 1990
 1990-1991 Member, International Program Committee, Seventh International Conference on AIDS, Florence, Italy, 1991
 1992-Present External Advisory Committee, NIH Program for Minority Research Institutes, Meharry Medical College, Nashville, Tennessee
 1994 Reviewer, Innovative Research Grant Application, Lottery Health Research, Wellington, New Zealand
 1994-1997 Scientific Advisory Board, International Business Conferences, Southboro, Massachusetts
 1995 Reviewer, University of Hawaii Office of Technology Transfer and Economic Development Seed Capital Program
 1995-1997 Reviewer, Gordon Research Conferences, University of Rhode Island, W. Kingston, Rhode Island
 1997-Present Scientific Advisory Committee, American Foundation for AIDS Research
 2001-Present External Reviewer, Institute of Medicine/National Academy of Sciences Task Force on Vaccine Safety Issues
 2001-Present External Advisory Committee, Resource for Nonhuman Primate Cell Depleting Antibodies a National Center for Research Resource, Harvard Medical School, Boston, MA
 2001 Reviewer, Kentucky Science and Engineering Foundation.

Professional Scientific Activities: (continued)

2002 Reviewer, Medical and Scientific Advisory Board, Shwachman-Diamond Syndrome International
 2003 External Advisory Committee, COBRE grant on "Structural Relationships in Infectious Disease", Oklahoma State University, Stillwater, OK
 2003 Member, State of Texas, Department of Health, Committee on State of Health and Preparedness

Study Sections:

1987-1997 NIH Small Business Innovative Research Grants
 1987-1989 NIAID Special Review Committee on AIDS and Related Research-Review Group
 1988 NIAID Special Review Committee on AIDS & Related Research Groups
 1988 Chairman, Cell Biology and Physiology Special Study Section, NIH
 1988 Ad hoc Reviewer for NHLBI grants on Diagnostics for Blood-borne Pathogens
 1989 Ad hoc Reviewer for NIDR Centers for Dental Caries Research
 1989 Ad hoc Reviewer for Veterans Administration Grants
 1989 Ad hoc Reviewer, Experimental Virology Special Study Section, NIH
 1990 Ad hoc Reviewer NIDR Special Program on AIDS
 1990 Chairman, Immunobiology Special Study Section, NIH
 1991 Ad hoc Reviewer NIDR Postdoctoral Fellowship Applications
 1991 NIAID Special Review Committee on Molecularly Targeted Approaches to Antiviral Therapy
 1991 Allergy and Immunology Special Study Section, NIH
 1992 Chairman, NIAID Special Review Committee on Enhancing Vaccine Immunogenicity
 1992 NHLBI Hematology Study Section (AHR-51), NIH
 1992 NIDR AIDS and Related Research, Special Study Section
 1993 Chairman, NIAID Special Review Committee on Research on the Molecular Immunology of Sexually Transmitted Diseases
 1993 NIAID Special Review Committee on Antigenic Variations of HIV-1 and Related Lentiviruses
 1993 Chairman, NIAID Special Review Committee on Mucosal Immunity in the Human Female Reproductive Tract
 1993 Chairman, NIAID Special Review Committee on Pediatric AIDS Clinical Trials Groups
 1993 NCI Special Review Committee on HTLV-I Induced Human Disease: Protective Immune Responses and Potential for Vaccine Development
 1994-Present Reviewer, Merit Review Applications, Department of Veteran Affairs
 1994 NIAID Special Review Committee on Molecular and Structural Approaches to Antiviral Drug Design
 1995 Reviewer, Career Development Application, Department of Veteran Affairs
 1995 Special Reviewer, AIDS & Research Related Study Section 7
 1995 NHLBI Special Review Committee on Molecular Diagnosis of Blood Borne Viral Pathogens
 1996 NIAID Special Review Committee on Nonhuman Primate Models to Evaluate AIDS Therapies
 1997 NHLBI Special Review Committee on Human Anti-HIV Monoclonal Antibodies in Immunotherapy
 1997 Reviewer, Career Development Application, Department of Veteran Affairs
 1997 Ad hoc Reviewer, Virology Study Section, NIH
 1997 Reviewer, AmFAR Special Study Section
 1997 Reviewer, Special Emphasis Panel, Centers for AIDS Research, DAIDS, NIAID, NIH
 1998 Reviewer, Special Emphasis Panel, Novel HIV Therapies: Integrated Preclinical/Clinical Program, NIAID, NIH
 1998 Reviewer, Special Emphasis Panel, Centers for AIDS Research, DAIDS, NIAID, NIH
 1998 Reviewer, Special Emphasis Panel, Endothelial Cell dysfunction in HIV infection, NHLBI, NIH
 1998 Reviewer, Establishment Grant Applications, Alberta Heritage Foundation for Medical Research, Canada
 1998 Reviewer, Innovative Cooperative Grant Applications, Human Frontier Science Program Organization, European Economic Commission
 1999 Reviewer, California Statewide AIDS Task Force, California Centers for AIDS Research
 1999 Reviewer, Special Targeted Request for Proposals on Vaccine Development and Immune Reconstitution, AmFAR
 1999 Reviewer, Special Emphasis Panel, Novel HIV Therapies: Integrated Preclinical/Clinical Program, NIAID
 1999 Reviewer, Special Emphasis Panel, HIV Vaccine Design and Development Teams, NIH, NIAID

Study Sections: (continued)

1999-present NIH Small Business Innovative Research Grants
 2000 Ad hoc Reviewer, Microbiology and Infectious Disease Research Committee, NIH
 2000 Reviewer, Special Emphasis Panel on Training Grants in Microbial Pathogenesis, NIH
 2000 Ad hoc Reviewer, Brain Disorders and Clinical Neuroscience (BDCN)-3 Study Section, NIH
 2000 Chairman, Special Emphasis Panel, Integrated Preclinical-Clinical Program: Novel HIV Therapies, NIH/NIAID
 2000 Reviewer, Source Selection Group: HIV Vaccine Design and Development Teams, NIH/NIAID
 2000 Reviewer, Medical Research Council of Canada, Interdisciplinary Research Team, Ottawa, Canada
 2000 Reviewer, Special Emphasis Panel, Center for Scientific Review, Immunology IRG Special Study Section, NIH
 2000 Reviewer, Special Emphasis Panel, Interdisciplinary Research Teams for Molecular Target Assessment, NIH/NCI
 2000 Chairman, Special Emphasis Panel, Simian Vaccine Evaluation Units, NIH/NIAID
 2000 Reviewer, Special Emphasis Panel, Novel Approaches to Cancer Therapy, NIH/NCI
 2000 Reviewer, American Foundation for AIDS Research, New York, NY
 2001 Reviewer, Special Emphasis Panel, Center for Scientific Review, Immunology IRG Special Study Section, NIH
 2001 Ad hoc Member, Canadian Institute of Health Research Review Committee Advisory Panel
 2001 Reviewer, Special Emphasis Panel, NCI Program Project Application in Cancer Immunotherapy, NIH
 2001-Present Reviewer American Foundation for AIDS Research, New York, NY
 2001 Reviewer, Biotechnology Engagement Program, Department of Health and Human Services
 2001 Reviewer, Subcommittee C – Basic & Preclinical Initial Review Group, NCI
 2001-Present Reviewer, Department of Defense Breast Cancer Initiative, Cell Biology Subcommittee
 2001 Reviewer, Immunology IRG Special Study Section 4, NIH
 2001 Reviewer, Subcommittee C, GRB-2 (64), NCI
 2001 Reviewer, Subcommittee C, GRB-P (X4), NCI
 2001-Present Member, Canadian Institute of Health Research Group Grants Review Panel
 2002 Reviewer, Subcommittee C, GRB (D3), NCI
 2002 Reviewer, Subcommittee C, GRB-P (K1), NCI
 2002 Reviewer, Canadian Network for Vaccines and Immunotherapies (CANVAC)
 2002-2003 Reviewer, Career Development Award, Department of Veteran Affairs
 2002-2003 Reviewer, AIDS Related Research ZRG1 Vacc 03 Subcommittee, NIH/NIAID
 2002-Present Member, Subcommittee C, Basic and Preclinical Sciences Review Group, NCI
 2002-2003 Reviewer, HIV and AIDS Special Study Section, NIH/NIDCR
 2003 Reviewer, Subcommittee C, GRB-I (S1), NCI

Site Visit Member:

1987 UCSF, Multidisciplinary Program on AIDS, NIAID, San Francisco, CA
 1988 IDEC Pharmaceutical, SBIR Phase II Application Review, NIH, Palo Alto, CA
 1990 Temple University, Special Program on AIDS, NIDR, Philadelphia, PA
 1990 Meharry Medical College, Minority Research Program in AIDS, NIH, Nashville, TN
 2000 University of Pennsylvania, NCI Program Project Application, NIH, Philadelphia, PA
 2000 Yerkes Regional Primate Research Center, Primate Center Grant Application, NIH/NCCR, Atlanta, GA
 2002 Institute for Human Virology, University of Maryland Biotechnology Institute, NIH, Baltimore, MD
 2002 University of Pittsburgh, NCI Program Project Application, NIH, Pittsburgh, PA
 2002 Ohio State University, NCI Program Project Application, NIH, Columbus, OH
 2002 University of Wisconsin-Madison, NCI Program Project Application, NIH, Madison, WI
 2002 Canadian Network for Vaccines and Immunotherapeutics, Montreal, Canada
 2003 Torrey Pines Molecular Biology Institute, NCI Program Project Application, NIH, La Jolla, CA
 2003 Cleveland Clinic, NCI Program Project Application, NIH, Cleveland, OH
 2003 Washington University, NCI Program Project Application, NIH, St. Louis, MO

Ad Hoc Reviewer:

Journal of Infectious Disease

Ad Hoc Reviewer (continued)

Science Magazine
Journal of Immunology
Journal of Immunological Methods
EMBO Journal
Hepatology
CRC Reviews of Immunology
Cell
Infection and Immunity
Journal of Clinical Investigation
Immunology Today
Proceedings of the National Academy of Science
Peptide Research
AIDS
Digestive Diseases and Sciences
Life Sciences Journal
Hybridoma
Cancer Research
Archives of Virology
Journal of Virology
Scandinavian Journal of Immunology
DNA and Cell Biology
Molecular Immunology
Critical Reviews in Immunology
Vaccine Research
Clinical and Diagnostic Laboratory Immunology
Developmental and Comparative Immunology
FEMS Immunology and Medical Microbiology
Nature Medicine
Clinical Cancer Research
British Journal of Cancer
Blood
Clinical and Experimental Immunology
The Immunologist
Investigative Ophthalmology and Visual Science
Oncogene
Antiviral Research
Vaccine

Editorial Boards:

International Reviews of Immunology, editorial board, 2000-Present
Clinical and Diagnostic Laboratory Immunology, editorial board, 1996-Present
Viral Immunology, editorial board, 1994-2000
Biologicals, advisory board, 1990-Present
Biotechniques, associate editor, 1986-2002
AIDS Research and Human Retroviruses, associate editor, 1987-Present
Viral Immunology, Founding editor, co-editor, 1987-1993
Laboratory Management, associate editor, 1987-1989
Focus on Vaccines, CRC Press, advisory board, 1988-Present
Diagnostics and Clinical Testing, advisory board, 1989-1990
Journal of Biological Standardization, advisory board, 1989-1990

Meetings Organized:

1984 High Technology Route to Viral Vaccines, Houston, Texas. G.R. Dreesman and R.C. Kennedy, Directors
Idiotypic Networks and Immune Regulation I: Potential Uses in Vaccines and in Understanding Human Disease, San Antonio, Texas, Dec. 3-6, 1985. R.C. Kennedy and G.R. Dreesman, Directors
Idiotypic Networks and Immune Regulation II: Autoimmunity, Cancer, Receptors and Vaccines, San Antonio, Texas, Nov. 18-20, 1987. R.C. Kennedy, Director

Sponsorship of Candidates for Postgraduate Degree:

M.S. Schick, Ph.D., 1984-1989 Dissertation title: The murine humoral immune response to hepatitis B surface antigen: Idiotype network pathways.

H. Wolf, Ph.D., 1987-1992 Dissertation title: The humoral immune response in man, chimpanzee, and mouse to HIV-1 gp 160.

R.K. Bright, Ph.D., 1990-1994 Dissertation title: SV40 induced tumors in mice: A model for the comparison of active vaccination strategies. (Recipient of the 1995 Armand J. Guarino Award for Academic Excellence in Doctoral Studies).

Sponsorship of Postdoctoral Fellows:

P.J. Frenchick	1984-1985
R. Simmonds	1984-1986
E.M. Zhou	1986-1988
R. Attanasio	1987-1991
R. Brown	1990-1991
R. Mernaugh	1990-1991
K. Lohman	1988-1992
R. Warren	1988-1994
P. Thompson	1992-1994
B. Smith	1995-1996
P. Benton	1996-1998
G. Kanmogne	1998-2003

Committees of Non-Thesis Masters' Degree Students:

Camille Anderson M.S. Conferred 1997

Sponsorship of Undergraduate Students:

Gregory Stunz, Division of Life Sciences, University of Texas at San Antonio, 1988-1990

Dennis Dilley, Department of Biology, St. Mary's University, 1988-1990

Claire Nypayer, Division of Life Sciences, University of Texas at San Antonio, 1989-1991

Brian Skrobarcek, Division of Life Sciences, University of Texas at San Antonio, 1990-1992

Myria Arnias, Division of Life Sciences, University of Texas at San Antonio, 1991-1992

Gregory Farris, Department of Biology, Our Lady of the Lake University, San Antonio, 1991-1994

Travis Rose, Department of Zoology, University of Oklahoma 1995-1996. Honors Research Thesis, "Differential Growth and Infectivity of Primary HIV-1 isolates."

Ahang Derakhshan, Department of Biology, University of Central Oklahoma, 1997-1998

Nathan Dailey, Department of Microbiology and Botany, University of Oklahoma, 1998-1999

Svetlana Lazaro, Department of Botany and Microbiology, University of Oklahoma, sponsor for honors thesis on "SV40 Tag tumor immunity."

Kristen Day, Department of Botany and Microbiology, University of Oklahoma, sponsor for honors thesis on "Antibodies mediate tumor immunity." 2001 Recipient of the Carl Albert Award for the Outstanding Senior in the University of Oklahoma College of Arts and Sciences. Recipient of a Fullbright Scholarship to perform research in Nairobi, Kenya.

Devin Lowe, Department of Biology, Texas Tech University, Howard Hughes Medical Institute undergraduate, 2002-Present

Summer Undergraduate Research and Education Program:

Kami Rynders, Department of Biology, University of Central Arkansas, Conway, Arkansas, 1995

Kimberly Lambert, Department of Biology, Harding University, Searcy, Arkansas, 1996

Alberto Pena, Department of Zoology, University of Oklahoma, Norman, Oklahoma, 1997

Robin Dark, Department of Biology, Eastern Central University, Ada, Oklahoma, 1998

Amy Ballard, Department of Biology, Abilene Christian University, Abilene, Texas, 2002

Graduate Student Special Studies:

Sean K. Bauman, 1996
Charles Van de Wiele, 1996
Allison Watts, 1996
Ming Siang Sung, 1997
Tracey McGaha, 1997
Scott Hefty, 1997
Russell J. DaVault, 1997
Kasie Nichols, 1998
James Papin, 2001
Jagadish Hegde, 2001
James Tarbox, 2001
Hyun-Seok Kang, 2001

Sponsorship of Visiting Professors:

Dr. Habib Zaghouni, Department of Microbiology, Mt. Sinai School of Medicine, New York, 1989
Dr. W.M.M.M. Nkya, Department of Infectious Diseases, Kilimanjaro Christian Medical Center, Moshi, Tanzania, 1990
Dr. John Shao, Department of Medicine, Muhimbili Medical Center, University of DareSalaam, DareSaalam, Tanzania, 1990
Dr. Paola Lanza, Department of Medicine, University of California, San Diego, 1993
Dr. Hiroyuki Tsuda, Chief, Division of Hematology and Immunology, Kumamoto City Hospital, Kumamoto City, Japan, 1994
Dr. Robin Simmonds, Department of Microbiology, University of Otago, Dunedin, New Zealand, 1995
Dr. Kenji Shirano, Division of Hematology and Immunology, Kumamoto City Hospital, Kumamoto City, Japan, 1996
Dr. Toshi Yamabe, Division of Cardiovascular Surgery, Kumamoto City Hospital, Kumamoto City, Japan, 1999

Relevant Teaching Experience:

Lecturer – Undergraduate:

General Microbiology (R.C. Kennedy, instructor), 3 credit hours, 1981
Immunology (A.A. Benedict, instructor, University of Hawaii), 1980-1981
Pathogenic Microbiology 450 (J.T. Douglas, instructor, University of Hawaii), 1981
Immunology (R. Hyde, instructor, University of Oklahoma), 1995-2001

Lecturer – Graduate and Medical Students:

Medical Microbiology, MMIC 6090, 2001-Present
Advanced Immunology, MI-6843 (Coordinator), 1996-1999
Advanced Immunology, MI-6843 (W. Hildebrand, Coordinator), 2000
Virology, MI-6303 (Coordinator), 1995-1998
Advanced Virology, MI-6303 (Coordinator), 1999-2001
Seminar in Microbiology and Immunology, MI-5971 (R.C. Kennedy, Coordinator), 1996
Medical Microbiology and Immunology Laboratory (Medical Students), 1995-Present
Medical Microbiology and Immunology Lecturer (Medical Students), 1995-Present
Medical Microbiology and Immunology Lecturer (Dental Students), 2000
Biochemistry, BI-5224 (P. DeAngelis, Coordinator), 1995-1999
Immunology, MI-6243 (B. Blackstock, Coordinator), 1995-2001
Host Parasite Interactions, MI-6403 (M. Cunningham, Coordinator), 1995-1998
Microbial Pathogenesis, MI-6405 (J. Murphy, Coordinator), 2000-2001
Guest Lecturer in Immunology and AIDS, Second year Medical Students, Universitat de Autonamo Guadalajara, Guadalajara, Mexico, 1997-Present
Guest Lecturer in Immunology, Graduate Immunology Class, University of Tennessee, Knoxville, Tennessee, 1999
Guest Lecturer in Graduate Cell Biology Class, University of Iowa, Iowa City, Iowa, 1995
General Virology (C. Gaunt, Coordinator), 1985-1994

Lecturer-Graduate and Medical Students: (continued)

Microbiology Pathogenesis (J. Alderete, Coordinator), 1986-1994
 Guest Lecturer in Immunology, Second year Medical Students, Meharry Medical College, 1992
 Tumor Virology (J.S. Butel, Coordinator), 1983

Laboratory Courses (Teaching Assistant)

General Microbiology (Micro 130) 1976-1978
 Immunology 461 1978-1980
 Pathogenic Microbiology 1978-1980

Ph.D. Dissertation Committees:

Kay Medina	1996-1999, Ph.D., OUHSC, 1999
Kendra White	1995-1996, Ph.D., OUHSC, 1996
Alice I. Sato	1996 (Immunology, outside member, University of Pennsylvania)
Kiley Prillman	1996-1998, Ph.D., OUHSC, 1998
Scott Hefty	1998-1999, M.S., OUHSC, 1999 (Major Advisor)
Wilfred Marrisen	1996-1999, Ph.D., OUHSC, 1999
Laura Shepard	1996-2000, Ph.D., OUHSC, 2000
Melva Gonzalez	1996-2000, Ph.D., OUHSC, 2000
Brett Shepard	1996-2001, Ph.D., OUHSC, 2001
Sean Bauman	1997-2000, Ph.D., OUHSC, 2000
Charles Van de Wiele	1997-2001, Ph.D., OUHSC, 2001 (Major Academic Advisor)
Allison M. Watts	1997-2000, M.S., OUHSC, 1999 (Major Advisor)
Heather Hickman	1999-2001
Stacy Jones	2000-2003, Ph.D., OUHSC, 2003 (Department of Physiology)
Liliana Alfaya-virzi	2000-Present
Jennifer Harris	2002-Present

Institutional Committees:

Institutional Animal Care and Use Committee	1989-2000, 2002-present
Patent Committee	1990-1991
Promotions Committee	1990-1992
Patent and Intellectual Property Committee (Chair)	1993-1994
Science Education Awards Committee (Chair)	1993
Scientific Advisory Council	1994
Student Undergraduate Research Education Program Selection Committee	1995
Presbyterian Health Foundation Grant Application Review Committee	1995-1996, 1998-2000
Institutional Animal Care and Use Committee	1995-2001
Primate Utilization Committee (Chairman)	1995-2001
Search Committee, Chair of Microbiology and Immunology (Advisory Group)	1996-1997
Search Committee, Robinson Endowed Chair of Gastroenterology	1996-1999
College of Medicine Alumni Association Research Review	1996-2000
Provost Basic Science Strategic Planning Committee	1996-2001
Biomedical Research Complex Equipment Committee	1997
Architectural and Engineering Committee	1998
Search Committee, Endowed Chair in Maternal-Fetal Medicine, Department of Obstetrics and Gynecology	2000
Promotion and Implementation Committee for the Basic Sciences	2000
Task Force on Anti-Terrorism and Public Safety	2001-present
Basic Research Science Building, Texas Tech University – El Paso	2001-present
Anti-Terrorism and Public Safety, Subcommittee on Public Health and University Partnership (Chair)	2002-present
Anti-Terrorism and Public Safety, Subcommittee on Anti-Terrorism Surveillance	2002-present

Departmental Committees:

Graduate Student Admissions and Assistantship Committee (Chair)	1995-1998
Honors and Awards Committee (Chair)	1995-1998
L.V. Scott Lecturer	1995-2001
Faculty Research Retreat	1996
Space Committee (Chair)	1996
Virology Faculty Search Committee (Chair)	1998-2000
Advisory Committee	1997-2000
Microbiology and Immunology Faculty Search Committee	2001-Present

Books-Edited:

Dreesman, G.R., Bronson, J.R., and Kennedy, R.C. High technology route to viral vaccines. *Amer. Society Microbiol.*, Washington, D.C., pp. 1-285, 1986.

Kennedy, R.C., and Koff, W.C. Concepts in Developing an AIDS vaccine. *International Reviews of Immunology, Volume 7*, Harwood Academic Publishers, New York, N.Y., pp. 1-120, 1990.

Koff, W.C., Wong-Staal, F., and Kennedy, R.C. *AIDS Research Reviews*. Marcel Dekker, New York, N.Y., Volume 1, pp. 1-455, 1991.

Koff, W.C., Wong-Staal, F., and Kennedy, R.C. *AIDS Research Reviews*. Marcel Dekker, New York, N.Y., Volume 2, pp. 1-393, 1992.

Koff, W.C., Wong-Staal, F., and Kennedy, R.C. *AIDS Research Reviews*. Marcel Dekker, New York, N.Y., Volume 3, pp. 1-344, 1993.

Shoenfeld, Y., Ferrone, S., and Kennedy, R.C. *Idiotypes in Medicine – Infections, Autoimmunity, and Cancer*. Elsevier Science, Amsterdam, The Netherlands, pp. 1-448, 1997.

Chairperson for Meetings:

Chairman	Session on Viral Immunology II, for IXth International Congress of Infectious and Parasitic Diseases, Munich, W. Germany, 1986
Co-chairman	Session on Idiotypic Vaccines for Idiotypic Networks and Immune Regulations II. San Antonio, Texas, 1987
Co-chairman	Session on Humoral Immunity, for National Cooperative Vaccine Development Groups on AIDS, Virginia Beach, Virginia, 1988
Chairman	Session on Vaccine for AIDS, for University of California, San Diego, Symposium on Viral Vaccines, 1988
Co-chairman	Session on Idiotypic Vaccines, for Idiotypes in Biology and Medicine, Gennep, Netherlands, 1989
Co-chairman	Session on Advances in HIV Vaccine Development for VIth International Conference on AIDS, San Francisco, California, 1990
Co-chairman	Session on HIV Infection and Therapeutic Modalities for Strategies to Control Retroviral Infections, Advances in Dermatology, San Diego, California, 1990
Chairman	Session on Host Immune Response for VIIth International Conference on AIDS, Florence, Italy, 1991
Chairman	Session on Immune Responses, Session VI, for International Conference on Advances in AIDS Vaccine Development, Marco Island, Florida, 1991
Co-chairman	AIDS Symposium Panel, Kumamoto City, Japan, 1993
Chairman	New Advances in Vaccine Technologies and Applications, International Business Communications Conference, Washington, D.C., 1994
Chairman	Novel Vaccine Strategies-Immune Based Treatment Strategies for HIV, International Business Communications Conference, Bethesda, Maryland, 1994
Chairman	Gene Therapy and Nucleic Acid Vaccine Strategies, International Business Communications Conference, Bethesda, Maryland, 1995
Co-chairman	DNA Vaccines: A New Era in Vaccinology, New York Academy of Sciences, Crystal City, Virginia, 1995
Chairman	Session on Primate Models and Studies for the International Meeting on Nucleic Acids Vaccines for Prevention of Infectious Diseases, Bethesda, Maryland, 1996
Chairman	Session on DNA Vaccines against Viral Agents, Genetic Vaccines and Immunotherapeutic Strategies, International Business Conferences, Washington, D.C., 1996

Chairperson for Meetings: (continued)

Chairman Session of DNA vaccines against Cancer, Gordon Research Conference on Genetic Vaccines, Plymouth State College, New Hampshire, 1997

Co-chairman Session on DNA vaccines and adjuvants, Harvard AIDS Institute Conference on HIV vaccines for Developing Countries, Dedham, Massachusetts, 1997

Co-chairman Session on Animals models for chronic hepatitis, HEP DART 2001, Frontiers in Drug Development for Viral Hepatitis, Maui, Hawaii, 2001

Co-chairman Session on Maternal-Fetal-Neonatal Considerations, Indo-U.S.A. Joint Working Group on Contraception and Reproductive Health Research, New Delhi, India, 2002

Chairman NCI Site Visit Review Panel, the Ohio State University, Columbus, OH, 2002

Co-chairman Session on Therapeutic and Preventive Vaccines, International Meeting of the Institute of Human Virology, Baltimore, MD, 2002

Evaluation of Individuals for Promotion:

Department of Pathology and Laboratory Medicine, University of Texas Health Science Center at Houston

Department of Medical Microbiology, King Faisal University, Saudi Arabia

Department of Pathology, Stanford University, Palo Alto, California

Department of Microbiology, Columbia University, New York, New York

Department of Microbiology, University of Texas Health Science Center at San Antonio

Department of Medicine, Division of Infectious Disease, Catholic University, Rome, Italy

Department of Microbiology and Immunology, Baylor College of Medicine, Houston, Texas

Department of Medical Microbiology and Tropical Medicine, University of Hawaii, John A. Burns School of Medicine, Honolulu, Hawaii

Department of Medicine, Uniformed Health Services University, Bethesda, Maryland

Department of Pathology, Vanderbilt University School of Medicine, Nashville, Tennessee

Department of Surgery, Duke University School of Medicine, Durham, North Carolina

Department of Pediatrics, University of Texas Health Science Center at San Antonio

Department of Retrovirology, Food and Drug Administration, Bethesda, Maryland

Division of Dermatology, Department of Medicine, University of California, San Diego School of Medicine

Department of Pediatrics, University of Southern California School of Medicine, Los Angeles, California

Department of Microbiology, University of Otago, Dunedin, New Zealand

Department of Pediatrics, University of Texas Health Science Center at San Antonio

Department of Physiology and Medicine, Southwest Foundation for Biomedical Research, San Antonio, Texas

Immunology Program, Wistar Institute, Philadelphia, Pennsylvania

Department of Ophthalmology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma

Department of Veterinary Sciences, University of Texas M.D. Anderson Cancer Center, Science Park, Bastrop, Texas

Division of Hematologic Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland

Department of Microbiology, University of Tennessee, Knoxville, Tennessee

Department of Microbiology and Immunology, Baylor College of Medicine, Houston, Texas

Department of Medicine, University of California, San Diego, California

Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania

Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma

Department of Molecular Biology, The Scripps Research Institute, La Jolla, California

Department of Veterinary Sciences, University of Texas M.D. Anderson Cancer Center, Houston, Texas

Program in Infectious Diseases, St. Judy Children's Hospital, Memphis, Tennessee

Department of Microbiology and Immunology, University of Arizona College of Medicine, Tucson, Arizona

Department of Medicine, Division of Infectious Diseases, Cornell University Medical Center, New York, New York

Department of Molecular Microbiology and Immunology, University of Missouri School of Medicine, Columbia, Missouri

Department of Microbiology and Immunology, University of Arizona College of Medicine, Tucson, Arizona

Department of Microbiology and Immunology, Louisiana State University Health Sciences Center, Shreveport, Louisiana

Current Grant Support: Principal Investigator

NIH P40-RR12317 – Baboon Research Resource Program, 1998-2003, \$4,091,783 total costs per year; \$522,218 direct costs per year

NIAID NO1-AI-95360 – Mapping and Characterization of Viral Epitopes, 1999-2004, W. Hildebrand, P.I., R.C. Kennedy, Co-P.I., \$251,831 direct costs per year

NIH R21-AI45391 – HIV gp120 Glycoconjugate Vaccines, 2000-2002, L.C. Paoletti, P.I., R.C. Kennedy, P.I. on Subcontract, \$34,738 direct costs per year

R03-HD38496 – Immunization against ACTH and parturition in baboons, 2000-2002, D.A. Myers, P.I., R.C. Kennedy, Co-P.I., \$100,000 total direct costs

Past Grant Support: Principal Investigator

- 1983-1984 **Biomedical Research Support Grant** – Idiotypic Networks in HBV Infection, \$15,000 direct cost
- 1985-1986 **Biomedical Research Support Grant** – Anti-Idiotypic Vaccines for HBV, \$15,000 direct cost
- 1985-1993 **U.S. Army Research and Development Command DAMD17-90-C-0067** – Use of synthetic peptides for controlling HIV infection, 1985 to 1993, \$106,441 direct costs per year
- 1986-1989 **NIH R01-AI23472** – Idiotypic Networks in Transfusion AIDS, \$552,461 total costs
- 1986-1989 **NIH U01-AI23619** – Anti-Idiotypic Modulation of HTLV-IIIb Infection, \$462,533 total costs
- 1987-1991 **HIVER, Ltd., London, U.K.** – Monoclonal Anti-CD4 Immunotherapy, \$2,000,000 total costs
- 1989-1993 **American Cancer Society, IM-566** - \$82,140 direct costs per year
- 1984-1992 **NIH R01-AI22307** – Idiotypic analysis of the immune response to HBV, \$792,533 total costs
- 1985-1993 **NIH P01-AI22380** – Program on Sexually Transmitted Diseases, J. Baseman, P.I., R.C. Kennedy, P.I. on project “Monoclonal anti-idiotypic vaccines to HBV,” \$90,012 total costs
- 1987-1994 **NIH P01-AI26462** – Strategy to develop idiotype based vaccines against HIV, \$6,060,503 total costs. National Cooperative Vaccine Development Group for AIDS
- 1991-1994 **NIH P30-AI28696** – Multidisciplinary Center for AIDS Related Research, \$1,973,000 total costs
- 1993-1994 **United Biomedical, Inc., Hauppauge, New York** – Immunogenicity of microparticle based vaccines for HIV, \$81,441 total costs
- 1995-1996 **North American Vaccine, Inc., Beltsville, Maryland** – Preclinical Safety and Evaluation of Meningococcal group B Polysaccharide Vaccines in Nonhuman Primates, \$123,585 total costs
- 1992-1997 **NIH R01-CA57957** – Candidate EBV vaccine in nonhuman primate models, 1992-1997, H.B. Jenson, P.I., R.C. Kennedy, P.I. on subcontract, \$32,978 total costs per year.
- 1996-1997 **Menarini Company, Rome, Italy** – Evaluation of a colony stimulating factor-erythropoietin hybrid molecule in nonhuman primates, \$253,799 total costs
- 1996-1997 **Lederle-Praxis Biologicals (Wyeth-Lederle Pediatric Vaccines), West Henrietta, New York** – A nonhuman primate model to evaluate pediatric vaccines, 1996-1997, \$439,921 total costs
- 1993-1998 **NIH N01-CA74101** – Neutralization assays on HIV, SIV, and SHIV, for assessment of HIV and SIV vaccine immunogenicity, \$1,171,511 total costs; \$150,573 direct costs per year
- 1997 **Siga Pharmaceuticals, Inc., New York, New York** – Immunogenicity and efficacy of a group A Streptococcal Vaccine, \$74,806 total costs
- 1993-1998 **U.S. Army Research and Development Command DAMD17-95-1-5029** – Developing Novel Conjugate HIV-1 Subunit Therapeutic Vaccines, \$2,211,647 total costs, former, P.I., P.I. on subcontract; \$99,714 direct costs per year
- 1993-1999 **NIH N01-AI35156** – Nonhuman primate model to study the effects of vaccines in pregnant females and their offspring, \$3,570,931 total costs
- 1998-2000 **Alliance Pharmaceutical/Mt. Sinai School of Medicine, San Diego, California** – Neonatal vaccination of baboons with an influenza based DNA vaccine, \$57,603 total costs
- 1996-2000 **NIH K08-EY00357** – Immunopathology of Adenovirus Keratitis, Physician Scientist Award, J. Chodosh, P.I., R.C. Kennedy, Mentor, \$582,709 total costs; \$122,680 direct costs per year
- 1998-2000 **United Biomedical Inc**—Evaluation of a multimeric HIV-1 peptide vaccine in baboons, \$22.230 total costs

Publications:

1. Kennedy, R.C., Sanchez, Y., Ionescu-Matiu, I., Melnick, J.L., and Dreesman, G.R. A common human anti-hepatitis B surface antigen idiotype is associated with the group a conformation-dependent antigenic determinant. *Virology* 122:219-221, 1982.

2. Kennedy, R.C. and Dreesman, G.R. Common idiotypic determinant associated with human antibodies to hepatitis B surface antigen. *J. Immunol.* 130:385-389, 1983.
3. Kennedy, R.C., Ionescu-Matiu, I., Adler-Storthz, K., Henkel, R.D., Sanchez, Y., and Dreesman, G.R. Characterization of anti-hepatitis B surface antigen monoclonal antibodies. *Intervirology* 19:176-180, 1983.
4. Kennedy, R.C., Adler-Storthz, K., Henkel, R.D., and Dreesman, G.R. Characteristics of a shared idiootype by two IgM anti-herpes simplex virus monoclonal antibodies that recognize different determinants. *J. Immunol.* 130:1943-1946, 1983.
5. Ionescu-Matiu, I., Kennedy, R.C., Sparrow, J.T., Culwell, A.R., Sanchez, Y., Melnick, J.L., and Dreesman, G.R. Epitopes associated with a synthetic hepatitis B surface antigen peptide. *J. Immunol.* 130:1947-1952, 1983.
6. Kennedy, R.C., Ionescu-Matiu, I., Sanchez, Y., and Dreesman, G.R. Detection of interspecies idiotypic cross-reactions associated with antibodies to hepatitis B surface antigen. *Eur. J. Immunol.* 13:232-235, 1983.
7. Kennedy, R.C., Dreesman, G.R., Sparrow, J.T., Culwell, A.R., Sanchez, Y., Ionescu-Matiu, I., Hollinger, F.B., and Melnick, J.L. Inhibition of a common human anti-hepatitis B surface antigen idiootype by a cyclic synthetic peptide. *J. Virol.* 46:653-655, 1983.
8. Kit, S., Trkula, D., Qavi, H., Dreesman, G.R., Kennedy, R.C., Adler-Storthz, K., Kaufman, R., and Adam, E. Sequential genital infections by herpes simplex virus types 1 and 2: restriction nuclease analyses of viruses from recurrent infections. *Sex. Transm. Dis.* 2:67-71, 1983.
9. Kennedy, R.C., Adler-Storthz, K., Henkel, R.D., Sanchez, Y., Melnick, J.L., and Dreesman, G.R. Immune response to hepatitis B surface antigen: Enhancement by prior injection of antibodies to the idiootype. *Science* 221:853-855, 1983.
10. Kennedy, R.C. and Dreesman, G.R. Production and characterization of anti-idiotypic reagents for the analysis of viral antigen systems. *J. Virol. Methods* 7:103-115, 1983.
11. Adler-Storthz, K., Kendall, C., Kennedy, R.C., Henkel, R.D., and Dreesman, G.R. Biotin-avidin-amplified enzyme immunoassay for detection of herpes simplex virus antigen in clinical specimens. *J. Clin. Microbiol.* 18:1329-1334, 1983.
12. Dreesman, G.R., Ionescu-Matiu, I., Sanchez, Y., Kennedy, R.C., Sparrow, J.T., and Melnick, J.L. Hepatitis B surface antigen polypeptide and synthetic peptide vaccines. In *Hepatitis B: the Virus, the Disease, and the Vaccine* (I. Millman, T.K. Einstein, and B.S. Blumberg, eds.), New York, Plenum Publishing Corp., 1984, pp. 215-224.
13. Kennedy, R.C. and Dreesman, G.R. Enhancement of the immune response to hepatitis B surface antigen: *in vivo* administration of anti-idiotypic induces anti-HBs that expresses a similar idiootype. *J. Exp. Med.* 159:655-665, 1984.
14. Kennedy, R.C., Melnick, J.L., and Dreesman, G.R. Antibody to hepatitis B virus induced by injecting antibodies to the idiootype. *Science* 223:930-931, 1984.
15. Kennedy, R.C., Adler-Storthz, K., Burns, J.W., Sr., Henkel, R.D., and Dreesman, G.R. Anti-idiotypic modulation of herpes simplex virus infection leading to increased pathogenicity. *J. Virol.* 50:951-953, 1984.
16. Dreesman, G.R., Sparrow, J.T., Kennedy, R.C., and Melnick, J.L. Immunogenic and antigenic activities of a cyclic synthetic HBsAg peptide. In *Modern Approaches to Vaccines. Molecular and Chemical Basis of Virus Virulence and Immunogenicity* (R.M. Chanock and R.A. Lerner, eds.), Cold Spring Harbor, N.Y., Cold Spring Harbor Laboratory, 1984, pp. 115-119.
17. Kennedy, R.C., Sparrow, J.T., Sanchez, Y., Melnick, J.L., and Dreesman, G.R. Enhancement of viral hepatitis B antibody (anti-HBs) response to a synthetic cyclic peptide by priming with anti-idiotypic antibodies. *Virology* 136:247-252, 1984.

18. Kennedy, R.C., Sparrow, J.T., Sanchez, Y., Melnick, J.L., and Dreesman, G.R. Enhancement of the immune response to a cyclic synthetic HBsAg peptide by prior injection of anti-idiotypic antibodies. *In Modern Approaches to Vaccines. Molecular and Chemical Basis of Virus Virulence and Immunogenicity* (R.M. Chanock and R.A. Lerner, eds.), Cold Spring Harbor, N.Y., Cold Spring Harbor Laboratory, 1984, pp. 427-430.
19. Kennedy, R.C. and Dreesman, G.R. Production of antibody to hepatitis B using only antibodies that are directed against anti-hepatitis B antibodies. *Gastroenterology* 87:736-737, 1984.
20. Melnick, J.L., Dreesman, G.R., Hollinger, F.B., Sparrow, J.T., Kennedy, R.C., Sanchez, Y., and Ionescu-Matiu, I. Synthetic peptide hepatitis B vaccine. *In Table Ronde Roussel-Uclaf, No. 48: Synthetic Vaccines.* Paris, Institut Scientifique Roussel, 1984, pp. 29-30.
21. Kennedy, R.C. and Dreesman, G.R. Immunoglobulin idiotypes: Analysis of viral antigen-antibody systems. *Prog. Med. Virol.* 31:168-182, 1985.
22. Dreesman, G.R. and Kennedy, R.C. Anti-idiotypic antibodies: Implications of internal image-based vaccines for infectious diseases. *J. Infect. Dis.* 151:761-765, 1985.
23. Henkel, R.D., Kennedy, R.C., Sparrow, J.T., and Dreesman, G.R. *In vivo* detection of human hepatoma secreting hepatitis B surface antigen in nude mice with radiolabeled monoclonal antibodies that recognize distinct epitopes. *Clin. Immunol. Immunopathol.* 35:146-155, 1985.
24. Kennedy, R.C., Lanford, R.E., Henkel, R.D., and Dreesman, G.R. Detecting herpes simplex I and II with biotin-avidin-amplified immunoassays. *Lab. Manage.* 23:53-55, 1985.
25. Kennedy, R.C., Dreesman, G.R., Butel, J.S., and Lanford, R.E. Suppression of *in vivo* tumor formation induced by simian virus 40-transformed cells in mice receiving anti-idiotypic antibodies. *J. Exp. Med.* 161:1432-1449, 1985.
26. Kennedy, R.C. Idiotypic networks in hepatitis B virus infections. *Curr. Topics Microbiol. Immunol.* 119:1-13, 1985.
27. Kennedy, R.C., Henkel, R.D., and Dreesman, G.R. Internal image-bearing anti-idiotypic antibodies as a potential vaccine against hepatitis B virus. *In Southwest Foundation for Biomedical Research International Symposium, 1st Annual*, Houston, Texas, 1985, Proceedings; High-technology route to viral vaccines (G.R. Dreesman, J.G. Bronson and R.C. Kennedy, eds.), Washington, D.C., ASM, 1985, pp. 109-116.
28. Dreesman, G.R., Sparrow, J.T., Frenchick, P.J., and Kennedy, R.C. Cyclic synthetic peptides and the immune response to hepatitis B virus. *In Southwest Foundation for Biomedical Research International Symposium, 1st Annual*, Houston, Texas, 1984, Proceedings; High-technology route to viral vaccines (G.R. Dreesman, J.G. Bronson and R.C. Kennedy, eds.), Washington, D.C., ASM, 1985, pp. 55-66.
29. Kennedy, R.C. and Dreesman, G.R. Antigen mimicry by anti-idiotypic antibodies that recognize a common anti-hepatitis B surface antigen idiotypic. *Adv. Exp. Med. Biol.* 185:139-147, 1985.
30. Dreesman, G.R., Sparrow, J.T., Frenchick, P.J., and Kennedy, R.C. Synthetic hepatitis B surface antigen peptide vaccine. *Adv. Exp. Med. Biol.* 185:129-137, 1985.
31. Kennedy, R.C., Dreesman, G.R., and Kohler, H. Vaccines utilizing internal image anti-idiotypic antibodies that mimic antigens of infectious organisms. *Biotechniques* 3:404-409, 1985.
32. Henkel, R.D., Dreesman, G.R., Kennedy, R.C., Howell, R.R., and Williams, J.C. Detection of human acidic H-glucosidase in fibroblasts using monoclonal antibodies in a biotin-avidin amplified ELISA. *Hybridoma* 4:351-360, 1985.
33. Pauletti, D., Simmonds, R., Dreesman, G.R., and Kennedy, R.C. Application of a modified computer algorithm in determining potential antigenic determinants associated with the AIDS virus glycoprotein. *Anal. Biochem.* 151:540-546, 1985.

34. Kennedy, R.C. and Dreesman, G.R. Anti-idiotypic antibodies as idiotope vaccines that induce immunity against infectious agents. *Int. Rev. Immunol.* 1:67-78, 1986.
35. Kennedy, R.C., Eichberg, J.W., and Dreesman, G.R. Lack of genetic restriction by a potential anti-idiotypic vaccine for type B viral hepatitis. *Virology* 148:369-374, 1986.
36. Shoenfeld, Y., Ben-Yehuda, O., Napartstek, Y., Wilner, Y., Frolichman, R., Schattner, A., Lavie, G., Joshua, H., Pinkhas, J., Kennedy, R.C., Schwartz, R.S., and Pick, A.I. The detection of a common idiotype on anti-DNA antibodies in the sera of patients with monoclonal gammopathies. *J. Clin. Immunol.* 6:194-204, 1986.
37. Kennedy, R.C., Eichberg, J.W., Lanford, R.E., and Dreesman, G.R. Anti-idiotypic antibody vaccine for type B viral hepatitis in chimpanzees. *Science* 232:220-223, 1986.
38. Kennedy, R.C., Henkel, R.D., and Dreesman, G.R. Further characterization of internal image-bearing anti-idiotypic antibodies: Specific binding to immunoglobulin receptors on murine hybridoma cells secreting antibodies to hepatitis B surface antigen. *Scand. J. Immunol.* 23:481-489, 1986.
39. Kennedy, R.C., Henkel, R.D., Pauletti, D., Allan, J.S., Lee, T.H., Essex, M., and Dreesman, G.R. Antiserum to a synthetic peptide recognizes the HTLV-III envelope glycoprotein. *Science* 231:1556-1559, 1986.
40. Kennedy, R.C., Eichberg, J.W., and Dreesman, G.R. Anti-idiotypic antibodies as a potential vaccine against hepatitis-B virus. *In Vaccines 86. New Approaches to Immunization.* Developing Vaccines Against Parasitic, Bacterial, and Viral Diseases. (F. Brown, R.M. Chanock, and R.A. Lerner, eds.), Cold Spring Harbor N.Y., Cold Spring Harbor Laboratory, 1986, pp. 85-89.
41. Eichberg, J.W., Lawlor, D.A., Kennedy, R.C., Dreesman, G.R., Alter, J.H., and Saxinger, W.C. Transmission of AIDS to chimpanzees: Infection, disease and immune response. *In Animal Models of Retrovirus Infection and Their Relationship to AIDS* (L.A. Salzman, ed.), N.Y. Academic Press, 1986, pp. 443-456.
42. Kennedy, R.C., Melnick, J.L., and Dreesman, G.R. Anti-idiotypes and immunity. *Scientific American*, 255:48-56, 1986.
43. Kennedy, R.C. and Dreesman, G.R. Protective immunization against hepatitis B virus infection with an anti-idiotypic vaccine. *In International Congress of Infectious and Parasitic Diseases, IXth, Munich, 1986, Proceedings, Vol. III: Parasitic Infections, Immunology, Mycotic Infections, General Topics.* (W. Marget, W. Lang, and E. Gabler-Sandberg, eds.), Munchen, MMV Medizin Verlag Munchen, 1986, pp. 116-118.
44. Kennedy, R.C., Zhou, E.-M., and Dreesman, G.R. Anti-idiotypic antibodies modulate the immune response to hepatitis B surface antigen. *In International Congress of Infectious and Parasitic Diseases, IXth, Munich, 1986, Proceedings, Vol. I: Viral Infections* (W. Marget, W. Lang, and E. Gabler-Sandberg, eds.), Munchen, MMV Medizin Verlag Munchen, 1986, pp. 49-51.
45. Lanford, R.E., Kanda, P., and Kennedy, R.C. Induction of nuclear transport with a synthetic peptide homologous to the SV40 T antigen transport signal. *Cell* 46:575-582, 1986.
46. Kennedy, R.C. New trends in vaccine development: Anti-idiotypic Antibodies. *In Proceedings of the Asian and Pacific Conference on Malaria* (W. Siddiqui, ed.), University of Hawaii Publishing Dept., 1986, pp. 339-351.
47. Dreesman, G.R. and Kennedy, R.C. Synthetic peptide vaccines, carriers and adjuvants. *In Proceedings of the Asian and Pacific Conference on Malaria* (W. Siddiqui, ed.), University of Hawaii Publishing Dept., 1986, pp. 352-361.
48. Kennedy, R.C., Chanh, T.C., Kanda, P., Eichberg, J.W., Allan, J.S., Lee, T.H., Essex, M., and Dreesman, G.R. Synthetic peptides identify native antigenic determinants associated with human T-lymphotropic virus type III. *Protides Biol. Fluids Proc. Colloq.* 34:107-111, 1986.
49. Kanda, P., Kennedy, R.C., and Sparrow, J.T. Immunization studies using resin-bound synthetic peptides. *Protides Biol. Fluids Proc. Colloq.* 34:125-128, 1986.

50. Chanh, T.C., Dreesman, G.R., Kanda, P., Linette, G.P., Sparrow, J.T., Ho, D.D., and Kennedy, R.C. Induction of anti-HIV neutralizing antibodies by synthetic peptides. *EMBO J.* 5:3065-3071, 1986.
51. Chanh, T.C., Kennedy, R.C., Alderete, B.E., Kanda, P., Eichberg, J.W., and Dreesman, G.R. Human immunodeficiency virus gp120 glycoprotein detected by a monoclonal antibody to a synthetic peptide. *Eur. J. Immunol.* 16:1465-1468, 1986.
52. Dreesman, G.R., Kennedy, R.C., Kanda, P., Chanh, T.C., Eichberg, J.W., Sparrow, J.T., Ho, D.D., Allan, J.S., Lee, T.H., and Essex, M. Synthetic HIV peptide vaccine candidates and protection studies in chimpanzees. In *Colloque des "Cent Gardes"*, 1st, Marnes-la-Coquette, Paris, France, 29-30 Octobre 1986, Proceedings; Retroviruses of Human-A.I.D.S. and Related-Animal Diseases (M. Girard, G. de The, and L. Valette, eds.), Lyon, Foundation Marcel Merieux, 1987, pp. 175-178.
53. Zhou, E.-M., Dreesman, G.R., and Kennedy, R.C. Anti-idiotypic antibodies: A new generation of vaccines against infectious agents. *Microbiol. Sci.* 4:36-40, 1987.
54. Kennedy, R.C., Dreesman, G.R., Chanh, T.C., Boswell, R.N., Allan, J.S., Lee, T.-H., Essex, M., Sparrow, J.T., Ho, D.D., and Kanda, P. Use of a resin-bound synthetic peptide for identifying a neutralizing antigenic determinant associated with the human immunodeficiency virus envelope. *J. Biol. Chem.* 262:5769-5774, 1987.
55. Dreesman, G.R., Eichberg, J.W., Chanh, T.C., and Kennedy, R.C. Use of vaccination in prevention of HIV infection. In *AIDS, Acquired Immune Deficiency Syndrome, and Other Manifestations of HIV Infection*. Epidemiology, Etiology, Immunology, Clinical Manifestations, Pathology, Control, Treatment and Prevention (Wormser, G.P., Stahl, R.E., and Bottone, E.J., eds.), Noyes Publications, Park Ridge, N.J., 1987, pp. 1037-1052.
56. Sela, O., El-Roeiy, A., Isenberg, D.A., Kennedy, R.C., Colaco, C.B., Pinkhas, J., and Shoenfeld, Y. A common anti-DNA idio type in sera of patients with active pulmonary tuberculosis. *Arthritis Rheum.* 30:50-56, 1987.
57. Schick, M.R., Dreesman, G.R., and Kennedy, R.C. Induction of an anti-hepatitis B surface antigen response in mice by noninternal image (Ab2 alpha) anti-idiotypic antibodies. *J. Immunol.* 138:3419-3425, 1987.
58. Ho, D.D., Sarngadharan, M.G., Hirsch, M.S., Schooley, R.T., Rota, T.R., Kennedy, R.C., Chanh, T.C., and Sato, V.L. Human immunodeficiency virus neutralizing antibodies recognize several conserved domains on the envelope glycoproteins. *J. Virol.* 61:2024-2028, 1987.
59. El-Roeiy, A., Sela, O., Isenberg, D.A., Feldman, R., Colaco, B.C., Kennedy, R.C., and Shoenfeld, Y. The sera of patients with Klebsiella infections contain a common anti-DNA idio type (16/6) Id and anti-polynucleotide activity. *Clin. Exp. Immunol.* 67:507-515, 1987.
60. Chanh, T.C., Dreesman, G.R., and Kennedy, R.C. Monoclonal anti-idiotypic antibody mimics the CD4 receptor and binds human immunodeficiency virus. *Proc. Natl. Acad. Sci. USA* 84:3891-3895, 1987.
61. Kennedy, R.C., Kanda, P., Dreesman, G.R., Eichberg, J.W., Chanh, T.C., Ho, D.D., and Sparrow, J.T. Properties of synthetic peptides that identify neutralizing epitopes on the HIV envelope glycoprotein. In *Vaccines 87: Modern Approaches to New Vaccines: Prevention of AIDS, and Other Viral, Bacterial, and Parasitic Diseases* (R.M. Chanock, R.A. Lerner, F. Brown, and H. Ginsberg, eds.), Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y., 1987, pp. 250-255.
62. Kennedy, R.C. Anti-idio type antibodies: Prospects in clinical and laboratory medicine. *Lab. Manage.* 25(8):33-41, 1987.
63. Kennedy, R.C., Zhou, E.-M., Lanford, R.E., Chanh, T.C., and Bona, C.A. Possible role of anti-idiotypic antibodies in the induction of tumor immunity. *J. Clin. Invest.* 80:1217-1224, 1987.

64. Dalglish, A.G., Thomson, B.J., Chanh, T.C., Malkovsky, M., and Kennedy, R.C. Neutralization of HIV isolates by anti-idiotypic antibodies which mimic the T4 (CD4) epitope: A potential AIDS vaccine. *Lancet* ii:1047-1050, 1987.
65. Kennedy, R.C., Dreesman, G.R., and Chanh, T.C. Synthetic peptides and anti-idiotypic antibodies for controlling human immunodeficiency virus infection. *In Biotechnology in Clinical Medicine; Papers presented at the International Symposium on Biotechnology in Clinical Medicine*, Rome, 1987 (A. Albertini, L. Lenfant, and R. Paoletti, eds.), Raven Press, New York, 1987, pp. 219-225.
66. Zhou, E.-M., Chanh, T.C., Dreesman, G.R., Kanda, P., and Kennedy, R.C. Immune response to human immunodeficiency virus. *In vivo* administration of anti-idiotypic induces an anti-gp160 response specific for a synthetic peptide. *J. Immunol.* 139:2950-2956, 1987.
67. Lee, S.H., Kanda, P., Kennedy, R.C., and Walker, J.R. Relation of the Escherichia coli DNAX gene to its two products-the τ and γ subunits of DNA polymerase III holoenzyme. *Nucleic Acids Res.* 15:7663-7675, 1987.
68. Eichberg, J.W., Zarling, J.M., Alter, H.J., Levy, J.A., Berman, P.W., Gregory, T., Laskey, L.A., McClure, J., Cobb, K.E., Moran, P.A., Hu, S.L., Kennedy, R.C., Chanh, T.C., and Dreesman, G.R. T-cell responses to human immunodeficiency virus (HIV) and its recombinant antigens in HIV-infected chimpanzees. *J. Virol.* 61:3804-3808, 1987.
69. Shoenfeld, Y., Vilner, Y., Reshef, T., Klajman, A., Skibin, A., Kooperman, O., and Kennedy, R.C. Increased presence of common system lupus erythematosus (SLE) anti-DNA Idiotypes (16/6 Id, 32/15 Id) is induced by procainamide. *J. Clin. Immunol.* 7:410-419, 1987.
70. El-Roeiy, A., Gleicher, N., Isenberg, D., Kennedy, R.C., and Shoenfeld, Y. A common anti-DNA idiotypic and other autoantibodies in sera of offspring of mothers with systemic lupus erythematosus. *Clin. Exp. Immunol.* 68:528-534, 1987.
71. Konikoff, F., Isenberg, D.A., Kooperman, O., Kennedy, R.C., Rauch, J., Theodor, E., and Shoenfeld, Y. Common lupus anti-DNA antibody idiotypes in chronic liver diseases. *Clin. Immunol. Immunopathol.* 43:265-272, 1987.
72. Teplizki, H., Kennedy, R.C., and Shoenfeld, Y. Vaccine for AIDS obstacles and approaches to solutions. *Harefuah. J. Isr. Med. Assoc.* (in Hebrew) 113:354-357, 1987.
73. Eichberg, J.W., Alter, H.J., Dreesman, G.R., Cobb, K.E., Kennedy, R.C., Chanh, T.C., Gregory, T., and Berman, P. AIDS in chimpanzees: Infection, disease, and cellular immune response. *In International Symposium on Viral Hepatitis and AIDS*, San Jose, Costa Rica, 1986, Proceedings; Viral Hepatitis and Acquired Immunodeficiency syndrome (V.M. Villarejos, ed.), Trejos Hermanos S.A., San Jose, Costa Rica, 1987, pp. 325-330.
74. Dreesman, G.R., Chanh, T.C., Eichberg, J.W., Kanda, P., Kennedy, R.C., Allan, J.S., and Essex, M. Preliminary HTLV-III vaccine candidates: Chimpanzee trials. *In International Symposium on Viral Hepatitis and AIDS*, San Jose, Costa Rica, 1986, Proceedings; Viral Hepatitis and Acquired Immunodeficiency syndrome (V.M. Villarejos, ed.), Trejos Hermanos S.A., San Jose, Costa Rica, 1987, pp. 69-72.
75. Eichberg, J.W., Montiel, M.M., Morale, B.A., King, D.E., Chanh, T.C., Kennedy, R.C., and Dreesman, G.R. Lymphocyte subsets in chimpanzees. *Lab. Anim. Sci.* 38:197, 1988.
76. Dalglish, A.G., Kennedy, R.C., Sattentau, Q., Chanh, T.C., Beverly, P., Maddon, P., Axel, R., and Malkovsky, M. The T4 molecule: Its possible use in therapeutic strategies against AIDS. *In Abbott-UCLA Symposium on Human Retroviruses, Cancer, and AIDS: Approaches to Prevention and Therapy*, Keystone, Colorado, 1987: Human Retroviruses, Cancer, and AIDS; Approaches to Prevention and Therapy (D. Bolognesi, ed.), (UCLA Symp. Mol. Cell. Biol. New Ser., vol. 71), New York, A.R. Liss, 1988, pp. 283-288.
77. Dalglish, A.G. and Kennedy, R.C. Anti-idiotypic antibodies as immunogens: idiotypic based vaccines. *Vaccine* 6:215-220, 1988.

78. Dreesman, G.R., Chanh, T.C., Eichberg, J.W., Kanda, P., Kennedy, R.C., Allan, J.S., and Essex, M. Definition of HIV determinants with vaccine potential. *In Abbott-UCLA symposium on Human Retroviruses, Cancer, and AIDS: Approaches to Prevention and Therapy*, Keystone, Colorado, 1987; Human Retroviruses, Cancer and AIDS: Approaches to Prevention and Therapy (D. Bolognesi, ed.), (UCLA Symp. Mol. Cell. Biol. New Ser., vol. 71), New York, A.R. Liss, 1988, pp. 341-347.
79. Chanh, T.C., Kennedy, R.C., and Kanda, P. Synthetic peptides homologous to HIV transmembrane glycoprotein suppress normal human lymphocyte blastogenic response. *Cell Immunol.* 111:77-86, 1988.
80. Dreesman, G.R., Henkel, R.D., Zhou, E.-M., and Kennedy, R.C. Properties of a protective anti-idiotypic vaccine for viral hepatitis B. *In International Convocation on Immunology*, 10th, Buffalo, N.Y., 1986; Vaccines: New Concepts and Developments (H. Kohler and P.T. LoVerde, eds.), Essex, U.K., Longman Scientific & Technical, 1988, pp. 352-358.
81. Zhou, E.-M., Wang, D.-R., and Kennedy, R.C. Anti-idiotypic antibodies as vaccines. *Chinese J. Immunol.* 2:6-14, 1988.
82. Lanford, R.E., Kennedy, R.C., Dreesman, G.R., Eichberg, J.W., Notvall, L., Luckow, V.A., and Summers, M.D. Expression of hepatitis B virus surface and core antigens using a baculovirus expression vector. *In International Symposium on Viral Hepatitis and Liver Disease*, Barbican Centre, London, 1987, Proceedings; Viral Hepatitis and Liver Disease (A.J. Zuckerman, ed.), New York, Alan R. Liss, 1988, pp. 372-378.
83. Kanda, P., Kennedy, R.C., and Lanford, R.E. Synthetic peptides identify a critical lysine residue in the SV40 nuclear transport signal. *In American Peptide Symposium*, 10th, St. Louis, Missouri, 1987, Proceedings; Peptides. Chemistry and Biology. Leiden, ESCOM, 1988, pp. 321-322.
84. Dalgleish, A.G., Chanh, T.C., Kennedy, R.C., Kanda, P., Clapham, P.R., and Weiss, R.A. Neutralization of diverse HIV-1 strains by monoclonal antibodies raised against a gp41 synthetic peptide. *Virology* 165:209-215, 1988.
85. Cauda, R., Tumbarello, M., Ortona, L., Kanda, P., Kennedy, R.C., and Chanh, T.C. Inhibition of normal human natural killer cell activity by human immunodeficiency virus synthetic transmembrane peptides. *Cell Immunol.* 115:57-65, 1988.
86. Kennedy, R.C., Chanh, T.C., Allan, J.S., Dreesman, G.R., Eichberg, J.W., Cauda, R., and Kanda, P. Overview on the use of synthetic peptides in human immunodeficiency virus infection. *Adv. Biotechnol. Processes* 10: 149-172, 1988.
87. Schick, M.R. and Kennedy, R.C. Anti-idiotypic antibodies and immunization against infectious diseases. *In Advanced Drug Delivery Reviews* (G. Poste, ed.), Elsevier Science Publications, Amsterdam, 1988, pp. 343-357.
88. El-Roeiy, A., Valessini, G., Friberg, J., Shoenfeld, Y., Kennedy, R.C., and Gleicher, N. Auto antibodies and common idiotypes in sperm antibody positive females and males. *Amer. J. Obstet. Gynecol.* 158:596-603, 1988.
89. Kennedy, R.C. and Chanh, T.C. Perspectives on developing anti-idiotypic based vaccines for controlling human immunodeficiency virus infection. *AIDS* 2:S119-S127, 1988.
90. Schick, M.R. and Kennedy, R.C. Methods for production and characterization of anti-idiotypic antibody reagents. *Meth. Enzymol.* 178:36-48, 1989.
91. Lanford, R.E., Luckow, V., Kennedy, R.C., Dreesman, G.R., Notvall, L., and Summers, M.D. Expression and characterization of hepatitis B virus antigen polypeptides in insect cells with Baculovirus expression system. *J. Virol.* 63:1549-1557, 1989.
92. Schick, M.R., Lohman, K.L., and Kennedy, R.C. Methods for generating reagents to examine idiotypic networks within anti-viral immune responses. *J. Virol. Meth.* 25:123-137, 1989.

93. Cupps, T.R., Haas-Smith, S.A., Gerin, J.L., Tibbles, J.L., and Kennedy, R.C. Anti-idiotypic modulation of the *in vitro* immune response to hepatitis B surface antigen following remote infection by hepatitis B virus in man. *Cell. Immunol.* 122:244-250, 1989.
94. Zhou, E.-M. and Kennedy, R.C. Strategies for developing vaccines against acquired immunodeficiency syndrome. *Biochim. Biophys. Acta* 989:301-313, 1989.
95. Ontano, L., Cauda, R., Tumbalero, M., Kanda, P., Chanh, T.C., and Kennedy, R.C. Glicoproteina di transmembrana dell'HIV (gp41) ed immunita' cellulo mediata. AIDS e Sindromi Correlate. *In II Convegno Nazionale* (Moroni, M., Aiuti, F., Esposito, R., and Lazzarin, A., eds.), Monduzzi Editore, Bologna, Italy, pp. 321-324, 1989.
96. Ortona, L., Cauda, R., Tumbarello, M., Kanda, P., Kennedy, R.C., and Chanh, T.C. Attivita' LAK (Lymphocyte Activated Killer) ed infezione da HIV. AIDS e Sindromi Correlate. *In II Convegno Nazionale* (Moroni, M., Aiuti, F., Esposito, R., and Lazzarin, A., eds.), Monduzzi Editore, Bologna, Italy, pp. 349-353, 1989.
97. Zhou, E.-M., Lohman, K., and Kennedy, R.C. Administration of noninternal image monoclonal anti-idiotypic antibodies induces idiotypic restricted responses specific for human immunodeficiency virus envelope glycoprotein epitopes. *Virology* 174:9-17, 1990.
98. Warren, R.Q., Wolf, H., Shuler, K., Eichberg, J.W., Zajac, R.A., Boswell, R.N., Kanda, P., and Kennedy, R.C. Synthetic peptides define the fine specificity of HIV gp160 humoral immune response in HIV-1 infected chimpanzees. *J. Virol.* 64:486-492, 1990.
99. Kennedy, R.C. and Attanasio, R. New concepts in viral vaccines: Idiotypic based strategies. *Sem. Virol.* 1:57-65, 1990.
100. Shearer, M.H., Lanford, R.E., and Kennedy, R.C. Monoclonal anti-idiotypic antibodies induce antibody responses specific for simian virus 40 large tumor antigen. *J. Immunol.* 145:932-939, 1990.
101. Kennedy, R.C., Chanh, T.C., Maino, V.C., Warner, N.L., and Koff, W.C. CD4-gp120 interaction: Idiotypic mimicry as putative vaccines and therapeutics against HIV infection. *In AIDS Vaccine: Basic Research and Clinical Trials* (S.D. Putney and D. Bolognesi, eds.), Marcel Dekker, New York, 1990, pp. 241-264.
102. Attanasio, R., Kennedy, R.C., Allan, J.S., Maino, V.C., Buck, D., and Kanda, P. Anti-idiotypic antibodies of a predefined specificity generated against a CDR3VH synthetic peptide defines a private anti-CD4 idiotypic. *Mol. Immunol.* 27:513-522, 1990.
103. Allan, J.S., Kanda, P., Kennedy, R.C., Cobb, E.K., Anthony, M., and Eichberg, J.W. Isolation and characterization of simian immunodeficiency viruses from two subspecies of African green monkeys. *AIDS Res. Human Retrovir.* 6:275-285, 1990.
104. Attanasio, R. and Kennedy, R.C. Idiotypic cascades associated with the CD4-HIV gp120 interaction: Principles for idiotypic-based vaccines. *Intern. Rev. Immunol.* 7:109-119, 1990.
105. Warren, R.Q. and Kennedy, R.C. Anti-idiotypic antibodies as potential viral vaccines. *Prog. Vaccinol.* 3:73-91, 1990.
106. Kennedy, R.C. Strategies to develop idiotypic based vaccines against hepatitis B virus and human immunodeficiency virus. *In Proceedings of Idiotypes in Biology and Medicine*, Elsevier Scientific Publications, 1990, pp. 273-278.
107. Kennedy, R.C. and Attanasio, R. Concepts of idiotypic based vaccines. *Can. J. Microbiol.* 36:811-816, 1990.
108. Cauda, R., Tumbarello, M., Ortona, L., Kennedy, R.C., Shuler, K.R., Chanh, T.C., and Kanda, P. Inhibition of lymphokine activated killer cell activity during HIV infection. *Nat. Immun. Cell Growth Regul.* 9:366-375, 1990.

109. Warren, R.Q., Wolf, H., Zajac, R., Boswell, R.N., Kanda, P., and Kennedy, R.C. Patterns of antibody reactivity to selected HIV-1 gp160 epitopes in infected individuals grouped according to CD4+ cell levels. *J. Clin. Immunol.* 11:13-21, 1991.
110. Attanasio, R., Allan, J.S., Anderson, S.A., Chanh, T.C., and Kennedy, R.C. Anti-idiotypic antibody response to monoclonal anti-CD4 preparations in nonhuman primate species. *J. Immunol.* 146:507-514, 1991.
111. Kennedy, R.C. The impact of idiotypic based strategies on cancer immunity. *In Human Cancer Immunology, Vol. 11*, (H.F. Oettgen, ed.), W.B. Saunders, Philadelphia, pp. 425-444, 1991.
112. Scinicariello, F., Attanasio, R., Laghi, V., and Kennedy, R.C. Idiotypes and anti-idiotypes: Potential applications in vaccines. *Biotechnol. Therap.* 2:107-122, 1991.
113. Tying, S.K., Cauda, R., Tumbarello, M., Ortona, L., Kennedy, R.C., Chanh, T.C., and Kanda, P. Synthetic peptides corresponding to sequences in HIV envelope gp41 and gp120 enhance *in vitro* production of interleukin-1 and tumor necrosis factor but depress production of interferon- α , interferon- τ , and interleukin-2. *Viral Immunol.* 4:33-42, 1991.
114. Zaghoulani, H., Goldstein, D., Shah, H., Anderson, S.A., Lacroix, M., Dionne, G., Kennedy, R.C., and Bona, C.A. Induction of antibodies to the envelope of human immunodeficiency virus by immunization of rabbits with monoclonal anti-idiotypes. *Proc. Natl. Acad. Sci. U.S.A.* 88:5645-5649, 1991.
115. Attanasio, R., Dilley, D., Buck, D., Maino, V.C., Kanda, P., and Kennedy, R.C. Structural characterization of a cross-reactive idiotypic shared by monoclonal antibodies specific for the CD4 molecule. *J. Biol. Chem.* 266:14611-14619, 1991.
116. Mernaugh, R.L., Bright, R.K., and Kennedy, R.C. Active immunization strategies using anti-idiotypic antibodies as vaccines for infection agents and cancer. *In Concepts in Vaccine Development* (R.L. Ellis, ed.), Butterworth Press, pp. 391-401, 1991.
117. Lohman, K.L., Carrillo, M.A., and Kennedy, R.C. Variable region gene sequence and selection of a mouse monoclonal anti-idiotypic antibody that detects a restricted idiotope on anti-HIV-1 gp160. *Gene* 105:283-284, 1991.
118. Kanda, P., Kennedy, R.C., and Sparrow, J.T. Synthesis of polyamide support for use in peptide synthesis and as peptide-resin conjugates for antibody production. *Int. J. Peptide Protein Res.* 38:385-391, 1991.
119. Attanasio, R., Lanford, R.E., Dilley, D., Stunz, G.W., Notvell, L., Henderson, A.B., and Kennedy, R.C. Immunogenicity of hepatitis B surface antigen derived from the baculovirus expression system. *Biologicals* 19:347-352, 1991.
120. Kanda, P., Schuler, K.R., Dunham, R.G., Boswell, R.N., Warren, R.Q., Kennedy, R.C., Shao, J.F., and Nkya, W.M.M.M. Comparison of humoral immune responses amongst groups of HIV-1 infected chimpanzees and humans directed toward a panel of HIV-1 gp160 synthetic peptides. *In Proceedings of the Twelfth American Peptide Symposium* (Peptides: Chemistry and Biology, J.A. Smith and J.E. River, eds.), pp. 715-716, 1992.
121. Anderson, S.A., Ostberg, L.G., Erhlich, P.H., and Kennedy, R.C. Characterization of private and cross-reactive idiotypes associated with human antibodies to hepatitis B surface antigen. *Intern. Immunol.* 4:135-145, 1992.
122. Warren, R.Q., Nkya, W.M.M.M., Shao, J.F., Anderson, S.A., Wolf, H., Hendrix, C.W., Kanda, P., Wabuke, M., Boswell, R.N., Redfield, R.R., and Kennedy, R.C. Comparison of antibody reactivity to HIV-1 gp160 epitopes by sera from HIV-1 infected individuals in Tanzania and the United States. *J. Clin. Microbiol.* 30:126-131, 1992.
123. Kennedy, R.C. Humoral immunity to HIV-1 gp160: Specificity analysis and anti-idiotypic modulation. *In Colloque des "Cent Gardes", 6th*, Marnes-la-Coquette, Paris, France, 1991, Proceedings; Retroviruses of the Human AIDS and Related Animal Diseases (M. Girard and L. Valette, eds.), Lyon, Foundation Marcel Merieux, 1992, pp. 235-240.

124. Nkya, W.M.M.M., Warren, R.Q., Wolf, H., Hendrix, C.W., Tesha, J., Redfield, R.R., Melcher, G.P., Burke, D.S., Kanda, P., and Kennedy, R.C. Fine specificity of the humoral immune response to HIV-1 gp160 in HIV-1 infected individuals from Tanzania. *J. Med. Virol.* 37:61-66, 1992.
125. Mernaugh, R.L., Shearer, M.H., Bright, R.K., Lanford, R.E., and Kennedy, R.C. Idiotype network components are involved in murine response to simian virus 40 large tumor antigen. *Cancer Immunol. Immunother.* 35:113-118, 1992.
126. Nixon, A., Zaghoulani, H., Penny, C., Lacroix, M., Dionne, G., Anderson, S.A., Kennedy, R.C., and Bona, C.A. The adjuvant effect of stearyl tyrosine on antibody response to a synthetic peptide corresponding to peptide 503-535 from HIV-1 gp160. *Viral Immunol.* 5:141-150, 1992.
127. Wolf, H., Warren, R.Q., Stunz, G.W., Shuler, K.R., Kanda, P., and Kennedy, R.C. Fine specificity of the murine antibody response to HIV-1 gp160 determined by synthetic peptides which define selected epitopes. *Mol. Immunol.* 29:989-998, 1992.
128. Chanh, T.C., Kennedy, R.C., and Hewetson, J.F. Anti-idiotypic vaccines in toxicology. *Int. J. Clin. Lab. Res.* 22:28-35, 1992.
129. Attanasio, R. and Kennedy, R.C. Structural correlates of immunoglobulin variable region antigenic determinants. *Bull. Inst. Pasteur* 90:165-174, 1992.
130. Warren, R.Q., Anderson, S.A., Nkya, W.M.M.M., Shao, J.F., Hendrix, C.W., Melcher, G.P., Redfield, R.R., and Kennedy, R.C. Examination of sera from HIV-1 infected individuals for antibodies corresponding to the principal neutralizing determinant of HIV-1 gp120 and *in vitro* neutralizing activity. *J. Virol.* 66:5210-5215, 1992.
131. Lohman, K.L., Attanasio, R., Buck, D.W., Carrillo, M.A., Allan, J.S., and Kennedy, R.C. Characterization of murine monoclonal anti-CD4: Epitope recognition, idiotype expression and variable region gene sequence. *J. Immunol.* 149:3247-3253, 1992.
132. Mernaugh, R.L., Bright, R.K., and Kennedy, R.C. Active immunization strategies using anti-idiotypic antibodies. *Biotechnology* 20: 391-403, 1992.
133. Kanda, P., Fritz, D.A., Dunham, R.G., Shuler, K.R., Lohman, K.L., Kennedy, R.C., and Buck, D. Comparison of the mouse antibody response to different antigenic formulations incorporating a synthetic peptide representing the heavy chain second complementarity determining region of a mouse monoclonal anti-CD4 antibody. *AIDS Res. Hum. Retrovir.* 8:1385-1386, 1992.
134. Attanasio, R., Kanda, P., Stunz, G.W., Buck, D.W., and Kennedy, R.C. Anti-peptide reagents identify a primary structure dependent cross-reactive idiotype expressed on heavy and light chains from a murine monoclonal anti-CD4. *Mol. Immunol.* 30:9-17, 1993.
135. Attanasio, R. and Kennedy, R.C. Structure and functional basis of monoclonal anti-receptor antibodies. In *AIDS Research Reviews, Vol. 3* (W.C. Koff, F., Wong-Staal, and R.C. Kennedy, eds.), Marcel Dekker, New York, N.Y. Chapter 15:291-304, 1993.
136. Warren, R.Q. and Kennedy, R.C. Fine specificity of the humoral immune response to HIV-1 gp160. In *AIDS Research Reviews, Vol. 3* (W.C. Koff, F. Wong-Staal, and R.C. Kennedy, eds.), Marcel Dekker, New York, N.Y. Chapter 11:207-217, 1993.
137. Bright, R.K., Shearer, M.H., and Kennedy, R.C. Comparison of the murine humoral immune response to recombinant SV40 large tumor antigen: Epitope specificity and idiotype analyses. *Cancer Immunol. Immunother.* 37:31-39, 1993.
138. Shearer, M.H., Bright, R.K., Lanford, R.E., and Kennedy, R.C. Immunization of mice with baculovirus derived recombinant SV40 large tumor antigen induces protective tumor immunity to a lethal challenge with SV40-transformed cells. *Clin. Exp. Immunol.* 91:266-271, 1993.

139. Warren, R.Q., Wolf, H., Stunz, G.W., and Kennedy, R.C. Antibody cross-reactivity to synthetic peptides representing the principal neutralizing determinant of HIV-1 varies among mouse strains immunized with recombinant gp160. *Exp. Clin. Immunogenet.* 26:630-638, 1993.
140. Attanasio, R., Allan, J.S., and Kennedy, R.C. Monoclonal anti-CD4 as immunoprophylactic agents for HIV infection. *J. Inf. Dis.* 168:515-516, 1993.
141. Warren, R.Q. and Kennedy, R.C. Vaccine strategies for HIV infection and AIDS. *In HIV Molecular Organization, Pathogenicity and Treatment* (J. Morrow and N. Haigwood, eds.), Elsevier Science Publisher, Amsterdam, pp. 365-378, 1993.
142. Lohman, K.L., Kieber-Emmons, T., and Kennedy, R.C. Molecular characterization and structural modeling of immunoglobulin variable regions from murine monoclonal antibodies specific for hepatitis B virus surface antigen. *Mol. Immunol.* 30:1295-1306, 1993.
143. Wong, M.T., Warren, R.Q., Anderson, S.A., Dolan, M.J., Hendrix, C.W., Blatt, S.P., Melcher, G.P., Boswell, R.N., and Kennedy, R.C. Longitudinal analysis of the humoral immune response to human immunodeficiency virus, type-1 (HIV-1) gp160 epitopes in rapid and nonprogressor subsets of individuals infected with HIV-1. *J. Inf. Dis.* 168:1523-1527, 1993.
144. Shearer, M.H., Bright, R.K., and Kennedy, R.C. Comparison of humoral immune responses and tumor immunity in mice immunized with recombinant SV40 large tumor antigen and a monoclonal anti-idiotypic. *Cancer Res.* 53:5734-5739, 1993.
145. Sylwester, A., Wessels, D., Schutt, D., Anderson, S.A., Warren, R.Q., Kennedy, R.C., and Soll, D.R. HIV-induced syncytia of a T cell line form single giant pseudopods and are motile. *J. Cell Sci.* 106:941-953, 1993.
146. Attanasio, R., Stunz, G.W., and Kennedy, R.C. Folding patterns of immunoglobulin molecules identified by urea gradient electrophoresis. *J. Biol. Chem.* 269:1834-1838, 1994.
147. Soll, D.R. and Kennedy, R.C. The role of T cell motility and cytoskeletal reorganization in HIV induced syncytium formation: A Perspective. *AIDS Res. Human Retrovir.* 4:325-327, 1994.
148. Kennedy, R.C. Idiotypic vaccine strategies. *In Synthetic Vaccines* (B.H. Nicholson, ed.), Blackwell Scientific Publications, Ltd., Oxford, U.K., pp. 376-393, 1994.
149. Kim, K.H., Park, M.K., Peeters, C., Shearer, M.H., Kennedy, R.C., and Nahm, M.H. Comparison of nonhuman primate antibodies against *Haemophilus influenzae* type b polysaccharide with human antibodies in oligoclonality and *in vivo* protective potency. *Infect. Immun.* 62:2426-2431, 1994.
150. Sadziene, A., Jonsson, M., Bergstrom, S., Bright, R.K., Kennedy, R.C., and Barbour, A.G. A bactericidal antibody to *Borrelia burgdorferi* directed against a variable region of the Osp B protein. *Infect. Immun.* 62:2037-2045, 1994.
151. Bright, R.K., Shearer, M.H., and Kennedy, R.C. Immunization of BALB/c mice with recombinant SV40 large tumor antigen induces antibody-dependent cell-mediated cytotoxicity (ADCC) against SV40 transformed cells: An antibody based mechanism for tumor immunity. *J. Immunol.* 153:2064-2071, 1994.
152. Bright, R.K., Shearer, M.H., and Kennedy, R.C. Fine specificity of the murine immune response to SV40 large tumour antigen utilizing synthetic peptides that define selected epitopes. *Clin. Exp. Immunol.* 96:491-499, 1994.
153. Shearer, M.H., Bright, R.K., and Kennedy, R.C. Molecular characterization of immunoglobulin variable regions from murine monoclonal antibodies specific for simian virus 40 large tumor antigen. *Scand. J. Immunol.* 40:415-422, 1994.
154. Bright, R.K., Shearer, M.H., and Kennedy, R.C. SV40 large tumor antigen associated synthetic peptides define native antigenic determinants and induce protective tumor immunity in mice. *Mol. Immunol.* 31:1077-1087, 1994.

155. Shoenfeld, Y., Amital, H., Ferrone, S., and Kennedy, R.C. Anti-idiotypes and their application under autoimmune, neoplastic, and infectious conditions. *Int. Arch. Allergy Immunol.* 105:211-223, 1994.
156. Shearer, M.H., Jenson, H.B., Carey, K.D., Chanh, T.C., and Kennedy, R.C. Production and characterization of murine monoclonal antibodies specific for baboon IgG heavy and light chains. *J. Med. Primatol.* 23:382-387, 1994.
157. McGee, J.P., Koff, W.C., Wang, C.Y., Potts, B., Kennedy, R.C., and O'Hagen, D.T. Controlled release microparticles with an entrapped branched V3 peptide from HIV-1: Assessment of immunogenicity in baboons. *In Proceedings of the International Symposium of Controlled Release Society* 21:871-873, 1994.
158. Zaghouani, H., Anderson, S.A., Sperber, K.E., Daian, C., Kennedy, R.C., Mayer, L., and Bona, C.A. Induction of antibodies to the human immunodeficiency virus type 1 by immunization of baboons with immunoglobulin molecules carrying the principal neutralizing determinant of the envelope protein. *Proc. Natl. Acad. Sci. USA* 92:631-635, 1995.
159. Warren, R.Q., Wong, M.T., Melcher, G.P., Blatt, S.P., Cahn, P., Perez, H., Zapiola, I., Bouzas, M.B., Muchnik, G., Anderson, S.A., and Kennedy, R.C. Serologic evaluation of HIV-1 infected individuals from Argentina and the United States indicates a similar distribution of subgroup B isolates. *J. Clin. Micro.* 33:481-483, 1995.
160. Wong, M.T., Thornton, D.C., Kennedy, R.C., and Dolan, M.J. A chemically defined liquid medium that supports primary isolation of *Rochalimaea (Bartonella) henselae* from blood and tissue specimens. *J. Clin. Micro.* 33:742-744, 1995.
161. Bright, R.K., Shearer, M.H., and Kennedy, R.C. Examination of lymphokines induced in mice following immunization with recombinant simian virus 40 large tumor antigen. *Cancer Immunol. Immunother.* 40:206-213, 1995.
162. Sylwester, A., Shutt, D., Wessels, D., Stapleton, J., Stites, J., Kennedy, R.C., and Soll, D.R. T cells and HIV induced T cell syncytia exhibit the same velocity cycle when translocating on plastic, collagen or endothelial monolayers. *J. Leuk. Biol.* 57:643-650, 1995.
163. Murphy, S., Sylwester, A., Kennedy, R.C., and Soll, D.R. Phagocytosis of individual CD4+ T cells by HIV-1 induced syncytia. *AIDS Res. Hum. Retrovir.* 11:433-442, 1995.
164. Newton, S.M., Joys, T.M., Anderson, S.A., Kennedy, R.C., Hovi, M.E., and Stocker, B. Expression and immunogenicity of an 18-residue epitope of HIV-1 gp41 as insert in the flagellar protein of a *salmonella* live vaccine. *Res. Microbiol.* 146:203-216, 1995.
165. Warren, R.Q., Wong, M.T., Melcher, G.P., Blatt, S.P., Zapiola, I., Bouzas, M.B., Muchnik, G., Anderson, S.A., and Kennedy, R.C. Presence of neutralizing antibodies to heterologous HIV-1 isolates in sera of infected individuals is not predictive of rate of disease progression. *Clin. Diag. Lab. Immunol.* 2:400-403, 1995.
166. Shearer, M.H., Robinson, E.W., VandeBerg, J.L., and Kennedy, R.C. Humoral immune response in a Marsupial *monodelphis domestica*: Anti-isotypic and anti-idiotypic responses detected by species specific monoclonal anti-immunoglobulin reagents. *Dev. Comp. Immunol.* 19:237-246, 1995.
167. Shutt, D., Stapleton, J., Kennedy, R.C., and Soll, D.R. HIV-induced syncytia in peripheral blood cell cultures crawl by extending giant pseudopods. *Cell. Immunol.* 166:261-274, 1995.
168. Bright, R.K., Shearer, M.H., and Kennedy, R.C. Nucleic acid vaccination against viral induced tumors. *Ann. N.Y. Acad. Sci.* 772:241-251, 1995.
169. Shearer, M.H., Stevens, F.L., Jenson, H.B., Chanh, T.C., Carey, K.D., White, G.L., and Kennedy, R.C. Cross-reactions among primate immunoglobulins. *Dev. Comp. Immunol.* 19:547-557, 1995.
170. Paoletti, L.C., Kennedy, R.C., Chanh, T.C., and Kaspar, D.L. Immunogenicity of group B *Streptococcus* type III-tetanus toxoid vaccine in baboons. *Infect. Immun.* 64:677-679, 1996.

171. Pass, H.I., Kennedy, R.C., and Carbone, M. Evidence for and implications of SV40-like sequences in human mesotheliomas. *Adv. Oncol.* 89:108, 1996.
172. Bright, R.K., Beames, B., Shearer, M.H., and Kennedy, R.C. Protection against a lethal tumor challenge with simian virus 40 transformed cells by the direct injection of DNA encoding SV40 large tumor antigen. *Cancer Res.* 56:1126-1130, 1996.
173. Prillman, K., Lawlor, D., Ellexson, M., McElwee, N., Confer, D., Cooper, D.K.C., Kennedy, R.C., and Hildebrand, W. Characterization of baboon class I major histocompatibility molecules: Implications for baboon-to-human xenotransplantation. *Transplantation* 61:989-996, 1996.
174. Shibata, R., Seimon, C., Cho, M.W., Arthur, L.O., Nigida, S.M., Matthews, T., Sawyer, L.A., Schultz, A., Murthy, K.K., Israel, Z., Javadian, A., Frost, P., Kennedy, R.C., Lane, H.C., and Martin, M.A. Resistance of previously infected chimpanzees to successive challenges with a heterologous intraclade B strain of HIV-1. *J. Virol.* 70:4361-4369, 1996.
175. Murthy, K.K., Cobb, E.K., El-Amad, Z., Satterfield, W., Lee, D.R., Kalish, M.L., Haigwood, N.L., Kennedy, R.C., Steimer, K.S., Schultz, A., and Levy, J.A. Titration of a vaccine stock preparation of HIV-1_{sf2} in cultured lymphocytes and in chimpanzees. *AIDS Res. Human Retrovir.* 12:1341-1348, 1996.
176. Kennedy, R.C., Shearer, M.H., Chanh, T.C., Jenson, H.B., and Stanley, J.R. Characterization of antibodies to hepatitis B surface antigen: Developing a nonhuman primate model to evaluate maternal therapeutic vaccination strategies during pregnancy. *Antiviral Therapy* 1(Suppl.4):76-83, 1996.
177. Simmonds, R., Pearson, L., Kennedy, R.C., and Tagg, J.R. Mode of action of a lysostaphin-like bacteriolytic agent produced by *Streptococcus zooepidemicus* strain 4881. *Appl. Environ. Microbiol.* 62:4536-4541, 1996.
178. Kennedy, R.C., Shearer, M.H., and Hildebrand, W. Nonhuman primate models to evaluate vaccine safety and immunogenicity. *Vaccine* 8:903-908, 1997.
179. Shearer, M.H., Lucas, A.H., Anderson, P.W., Carey, K.D., Jenson, H.B., Stanley, J.R., Chanh, T.C., and Kennedy, R.C. The baboon as a nonhuman primate model for assessing the effects of maternal vaccination with *Haemophilus influenzae* type b polysaccharide vaccines. *Infect. Immun.* 65:3267-3270, 1997.
180. Shearer, M.H., Corbitt, S.D., Stanley, J.R., White, G.L., Chodosh, J., Chanh, T.C., and Kennedy, R.C. Purification of secretory IgA from baboon colostrum. *J. Immunol. Meth.* 204:67-75, 1997.
181. Kennedy, R.C., Shearer, M.H., Hildebrand, W.H., and Simmonds, R.S. Nonhuman primates and their potential use in immunological based investigations. *The Immunologist* 5:150-156, 1997.
182. Watts, A.M., Shearer, M.H., Pass, H.I., and Kennedy, R.C. Development of an experimental murine pulmonary metastasis model incorporating a viral encoded tumor specific antigen. *J. Virol. Meth.* 69:93-102, 1997.
183. Simmonds, R.S., Shearer, M.H., and Kennedy, R.C. DNA vaccines: From principle to practice. *Parasitol. Today* 13:328-331, 1997.
184. Benton, P.A. and Kennedy, R.C. DNA vaccine strategies for the treatment of cancer. *Curr. Topics. Microbiol. Immunol.* 226:1-20, 1997.
185. Zaloudik, J., Miller, E., Nesbit, M., Wunner, W., Ernst-Grotkowski, C., Koido, T., Kennedy, R.C., Bergsaagel, P.L., Daly, J., and Herlyn, D.W. Expression of an antigen homologous to the human gastrointestinal carcinoma-associated antigen GA733 in normal tissues of experimental animals. *British Cancer J.* 76:909-916, 1997.
186. Shearer, M.H., Pass, H.I., Carbone, M., and Kennedy, R.C. Modulation of the immune response to simian virus 40 large tumor antigen via idiotypic-anti-idiotypic interactions. In *Idiotypes in Medicine: Autoimmunity, Infection and Cancer* (Y. Shoenfeld, R.C. Kennedy, and S. Ferrone, eds.), Elsevier Science, Amsterdam, pp. 317-329, 1997.

187. Kennedy, R.C. DNA vaccination for HIV and AIDS. *Nature Med.* 3:501-502, 1997.
188. Shutt, D.C., Jenkins, L.M., Carolan, E.J., Stapleton, J.T., Daniels, K.J., Kennedy, R.C., and Soll, D.R. T cell syncytia induced by HIV release a T cell chemoattractant: demonstration with a newly developed single cell chemotaxis chamber. *J. Cell. Sci.* 111:99-109, 1998.
189. Onderdonk, A.B. and Kennedy, R.C. Use of animal models for vaccine development. In *Vaccines: From concept to clinic. A guide to the development and testing of vaccines for human use* (L.L. Paoletti and P. McInnes, eds.), Harvard Medical Press, Cambridge, MA, 1998, pp. 19-42.
190. Bright, R.K., Shearer, M.H., Pass, H.I., and Kennedy, R.C. Immunotherapy of SV40 induced tumors in mice: A model for vaccine development. *Dev. Biol. Stand.* 94:341-353, 1998.
191. Shearer, M.H., Timanus, D.K., Benton, P.A., Lee, D.R., and Kennedy, R.C. Cross-clade inhibition of human immunodeficiency type 1 primary isolates by monoclonal anti-CD4. *J. Infect. Dis.* 177:1727-1729, 1998.
192. Watts, A.M. and Kennedy, R.C. Quantitation of tumor foci in an experimental murine tumor model using computer assisted video imaging. *Anal. Biochem.* 256:217-219, 1998.
193. Benton, P.A., Lee, D.R., and Kennedy, R.C. Sequence comparisons of nonhuman primate HIV-1 coreceptor homologues. *Mol. Immunol.* 35:95-101, 1998.
194. Watts, A.M., Stanley, J.R., Shearer, M.H., and Kennedy, R.C. Maternal and fetal vaccination strategies for hepatitis B surface antigen in nonhuman primate models: Evaluation of therapeutic modalities during pregnancy. In *Therapies for Viral Hepatitis* (R.F. Schinazi, J-P. Sommadossi, and H.C. Thomas, eds.), International Medical Press, London, U.K., pp. 185-193, 1998.
195. Chodosh, J., Nordquist, R.E., and Kennedy, R.C. Comparative anatomy of mammalian conjunctival lymphoid tissue: A putative mucosal immune site. *Dev. Comp. Immunol.* 22:621-630, 1998.
196. Shearer, M.H., Sureau, C., Dunbar, B., and Kennedy, R.C. Structural characterization of viral neutralizing antibodies to hepatitis B surface antigen. *Mol. Immunol.* 35:1149-1160, 1998.
197. Pass, H.I., Donington, J.S., Wu, P., Rizzo, P., Nishimura, M., Kennedy, R., and Carbone, M. Human mesotheliomas contain the simian virus-40 regulatory region and large tumor antigen DNA sequences. *J. Thorac. Cardiovasc. Surg.* 116:854-859, 1998.
198. Benton, P.A., Timanus, D.K., Shearer, M.H., White, G.L., Lee, D.R., and Kennedy, R.C. Analysis of nonhuman primate peripheral blood mononuclear cells for susceptibility to HIV-infection and HIV coreceptor expression. *Dev. Comp. Immunol.* 23:97-105, 1999.
199. Bot, A., Shearer, M.H., Bot, S., Garcia-Sastre, A., Woods, C., Limmer, J., Kennedy, R.C., Casares, S., and Bona, C. Induction of antibody response by DNA immunization of newborn baboons against influenza virus. *Viral Immunol.* 12:91-96, 1999.
200. Watts, A.M., Shearer, M.H., Pass, H.I., and Kennedy, R.C. Comparison of SV40 large T-ag recombinant protein and DNA immunization in the induction of protective immunity from experimental pulmonary metastasis model. *Cancer Immunol. Immunother.* 47:343-351, 1999.
201. Hefty, P.S. and Kennedy, R.C. Immunoglobulin variable regions as idiotypic vaccines. In *Infectious Disease Clinics of North America* 13:27-37, 1999.
202. Watts, A.M., Stanley, J.R., Shearer, M.H., Hefty, P.S., and Kennedy, R.C. Fetal immunization of baboons induces a fetal-specific antibody response. *Nature Med.* 5:427-430, 1999.
203. Weiner, D.B. and Kennedy, R.C. DNA vaccines. *Scientific American* 281:50-57, 1999.
204. Watts, A.M. and Kennedy, R.C. DNA vaccination strategies against infectious diseases. *Int. J. Parasitol.* 29:1149-1163, 1999.

205. Shearer, M.H., Dark, R.D., Chodosh, J., and Kennedy, R.C. Comparison and characterization of immunoglobulin G subclasses among primate species. *Clin. Diagn. Lab. Immunol.* 6:953-958, 1999.
206. Watts, A.M., Bright, R.K. and Kennedy, R.C. Antibody-Based Mechanisms of Tumor Immunity. *In The Antibodies* (J.D. Capra and M. Zannetti, eds.), Harwood Academic Publishers, Volume 5, pp. 31-62, 1999.
207. Kennedy, R.C. and Watts, A.M. Immunity to Bacterial Infections. *Encyclopedia of Life Sciences* Macmillian Publishers. Chapter 11, pp 106-115, 1999.
208. Paoletti, L.C., Pinel, J., Kennedy, R.C., and Kasper, D.L. Maternal antibody transfer in baboons and mice vaccinated with group B streptococcal polysaccharide conjugate. *J. Infect. Dis.* 181:653-658, 2000.
209. Shearer, M.H., Chanh, T.C., Dalgleish, A.G. and Kennedy, R.C. Idiotypic cascades associated with the CD4-HIV glycoprotein 120 interaction: immunization with anti-idiotypic antibodies induces anti-anti-idiotypic responses with anti-CD4 specificity and *in vitro* neutralizing activity. *AIDS Res. Hum. Retrovir.* 16:77-86, 2000.
210. Watts, A.M., Bright, R.K., and Kennedy, R.C. DNA cancer vaccination strategies target SV40 large tumour antigen in a murine experimental metastasis model. *Dev. Biol. Stand.* 104:143-147, 2000.
211. Jenson, H.B., Ench, Y., Gao, S.J., Rice, K., Carey, D., Kennedy, R.C., Arrand, J.R., and Mackett, M. Epidemiology of herpesvirus papio infection in a large captive baboon colony: similarities to Epstein Barr virus infection in humans. *J. Infect. Dis.* 181:1462-1466, 2000.
212. Watts, A.M., Shearer, M.H., Bright, R.K., and Kennedy, R.C. Vaccine. *In McGraw-Hill Yearbook of Science & Technology*, McGraw-Hill Publishers, New York, NY, pp. 407-411, 2000.
213. Ashbaugh, C.D., Moser, T.J., Shearer, M.H., White, G.L., Kennedy, R.C., and Wessels, M.R. Bacterial determinants of persistent throat colonization and the associated immune response in a primate model of group A streptococcal pharyngeal infection. *Cell Microbiol.* 2:283-292, 2000.
214. Kanmogne, G.D., Grammas, P., and Kennedy, R.C. Analysis of human endothelial cells and cortical neurons for susceptibility to HIV-1 infection and co-receptor expression. *J. Neurovirol.* 6:519-528, 2000.
215. Chodosh, J., Astley, R.A., Butler, M.G., and Kennedy, R.C. Adenovirus keratitis: a role for interleukin-8. *Invest. Ophthalmol. Vis. Sci.* 41:783-789, 2000.
216. Watts, A.M., Shearer, M.H., Bright, R.K., and Kennedy, R. C. Animal models of SV40 large tumor antigen induced tumors and immunotherapy using tumor specific antigen based strategies. *Recent Res. Devel. Cancer* 2: 257-270, 2000.
217. Sidebottom, D.A., Kennedy, R.C., and Hildebrand, W.H. Class I major histocompatibility complex expression in the yellow baboon. *J. Immunol.*, 166:3983-3993, 2001.
218. Kanmogne, G.D., Grammas, P., and Kennedy, R.C. Analysis of human lung endothelial cells for susceptibility to HIV-1 infection, coreceptor expression and cytotoxicity of gp120 protein. *AIDS Res. Hum. Retrovir.* 17:45-53, 2001.
219. Bot, A., Shearer, M., Bot, S., Avriette, M., Garcia-Sastre, A., White, G., Woods, C., Kennedy, R., and Bona, C. Induction of immunological memory in baboons primed with DNA vaccine as neonates. *Vaccine* 19:1960-1967, 2001.
220. Gryllos, I., Cywes, C., Shearer, M.H., Cary, M., Kennedy, R.C., and Wessels, M.R. Regulation of capsule gene expression by group A Streptococcus during pharyngeal colonization and invasive infection. *Mol. Microbiol.* 42:61-74, 2001.
221. Bright, R.K., Kimchi, E.T., Shearer, M.H., Kennedy, R.C., Carbone, M., and Pass, H.I. SV40 Tag-specific cytotoxic T lymphocytes generated from the peripheral blood of cancer patients: evidence for Tag-specific immunity against malignant pleural mesothelioma in humans. *Cancer Immunol. Immunother* 50:682-690, 2002.

222. Kanmogne, G.D., Kennedy, R.C. and Grammas, P. Infection of baboon microglia with SIV/HIV recombinant viruses: Role of CD4 and chemokine receptors.. *AIDS Res. Hum. Retrovir.* 18:557-565, 2002.
223. Chodosh, J. and Kennedy, R.C. The conjunctival lymphoid follicle in mucosal immunology. *DNA and Cell Biol.* 21:421-433, 2002.
224. Kanmogne, G.D., Kennedy, R.C., and Grammas, P. HIV-1 gp120 and gp160 peptides are toxic to brain endothelial cells and neurons: possible pathway for HIV entry into the brain and HIV-associated dementia. *J. Neuropath.Exp.Neurol.* 61:992-1000, 2002
225. Hefty, P.S., Brooks, C.S., Jett, A.M., White, G.L., Wikel, S.K., Kennedy, R.C., and Akins, D.R. The OspE-related, OspF-related and Elp lipoproteins are immunogenic in baboons experimentally infected with *Borrelia burgdorferi* and in human Lyme disease patients. *J. Clin. Microbiol.* 40:4256-4365, 2002.
226. Paoletti, L.C., and Kennedy, R.C. Neutralizing antibody is induced in mice by novel glycoconjugates of human immunodeficiency virus type 1 gp120 and env 2-3. *J. Infect. Dis.* 186:1597-1602, 2002.
227. Natarajan, K., Ghalayini, A.J., Sterling, R.S., Holbrook, R.M., Kennedy, R.C., and Chodosh, J. Activation of focal adhesion kinase in adenovirus-infected human corneal fibroblasts. *Invest. Ophthalmol Vis. Sci.* 43:2685-2690, 2002.
228. Wang, C.Y., Shen, M., Tam, G., Fang, X.D., Ye, J., Shen, F., Walfield, A.M., Wang, J.J.G., Li, M.L., Li, X.M., Salas, M., Shearer, M.H., Kennedy, R.C., and Hanson, C.V. Synthetic AIDS vaccine by targeting HIV receptor. *Vaccine* 21:89-97, 2002.
229. Kennedy, R.C. and Shearer, M.H. The role of antibodies in tumor immunity. *Intern. Rev. Immunol.* 22:1-32, 2003.
230. Kennedy, R.C., Shearer, M.H., and Bright, R.K. DNA vaccines as cancer treatment modalities. *Curr. Topics Microbiol. Immunol.* 2003, in press.
231. Kennedy, R.C., Shearer, M.H., Watts, A.M., and Bright, R.K. CD4+ T lymphocytes play a critical role in antibody production and tumor immunity against simian virus 40 large tumor antigen. *Cancer Res.* 63:1040-1045, 2003.
232. Lohman, K.L., Kieber-Emmons, T., Maino, V.C., and Kennedy, R.C. Potential mechanisms for the formation of functional D regions in murine monoclonal anti-CD4 heavy chain variable regions, submitted for publication.
233. Shutt, D.C., Stapleton, J.T., Daniels, K.J., Carolan, E.J., Kealy, G.P., Cedran, G.P., Kennedy, R.C., and Soll, D.R. Motile syncytia in the lymph nodes of HIV infected individuals, submitted for publication.
234. Benton, P.A., Jazaar, A., Harty, R., and Kennedy, R.C. Prevalence of hepatitis G viremia among patients with chronic hepatitis C disease, submitted for publication.
235. Watts, A.M., Bright, R.K., Shearer, M.H., and Kennedy, R.C. Fcγ receptors play a dominant role in protective tumor immunity in a murine model of experimental metastases, submitted for publication.
236. Dunbar, B.S., Skinner, S.M., Prasad, S., Shearer, M.H., and Kennedy, R.C. Hepatitis B vaccine: adverse reactions and molecular mechanisms, submitted for publication.
237. Joiner, W.S., Stanley, J.R., Shearer, M.H., and Kennedy, R.C. Characterization of the baboon immunoglobulin response to maternal and in utero fetal vaccination, submitted for publication.
238. Kennedy, R.C., Shearer, M.H., White, G.L., Butel, J.S., Dittmer, D., and Bright, R.K. Serologic evidence of simian virus 40 exposure in a captive colony of baboons, submitted for publication.

Abstracts:

Over 200 published abstracts of oral presentations and poster session contribution at various international, national, and local meetings.

Patents Issued:

1. Kennedy, R.C., Dreesman, G.R., and Essex, M. Synthetic peptides and method of use for diagnosis and vaccination for AIDS and ARC. U.S. Patent No. 4956273, Canadian Patent No. 1305828, E.P.O. No. 246362
2. Sparrow, J.T., Kanda, P., and Kennedy, R.C. Improved polyamide resin and method for preparation of reagents for immunodiagnostic use. U.S. Patent No. 4973638
3. Kanda, P., Kennedy, R.C., and Sparrow, J.T. Polyamide resin and method for preparation of reagents for immunodiagnostic use. U.S. Patent No. 5028675
4. Sparrow, J.T., Kanda, P., and Kennedy, R.C. Polyamide bound protide: Method of use thereof and kit. U.S. Patent No. 5084509
5. Kennedy, R.C., Dreesman, G.R., and Melnick, J.L. An anti-idiotypic vaccine for hepatitis B virus. E.P.O. Patent No. 110706
6. Kennedy, R.C., Dreesman, G.R., and Melnick, J.L. An anti-idiotypic vaccine for hepatitis B virus. Japanese Patent No. 59116230
7. Kennedy, R.C., Chanh, T.C., Beverly, P.C.L., Sattentau, Q.A., and Dalglish, A.G. Novel vaccines. E.P.O. Patent No. 287226
8. Sparrow, J.T., Kanda, P., and Kennedy, R.C. Composition of matter and method of immunizing against viral causative agents of AIDS and ARC. Canadian Patent No. 1293188

Patents Pending:

Co-inventor on nine patents which are currently pending.

Invited Presentations, 1981-1983:

1. Department of Virology and Epidemiology, Baylor College of Medicine, on "Chicken idiotypic specificities on induced antibodies define variable region phenotypic markers."
2. Department of Pathology, New York University Medical Center, on "Chicken idiotypes expressed on induced antibodies: Serologic tools to define variable region phenotypes."

Invited Presentations, 1984:

1. Division of Molecular Virology, Georgetown University, on "Serologic Recognition of a Cross-Reactive Idiotypic on Human Antibodies to Hepatitis B Surface Antigen."
2. Department of Microbiology, Pennsylvania State University, Hershey, PA, on "Anti-Idiotypes Induce Anti-Viral Humoral Immune Responses."
3. Department of Microbiology, University of Hawaii, Honolulu, HI, on "Modulation of Humoral Immune Responses by Anti-Idiotypic Antibodies."
4. Department of Veterinary Microbiology, Texas A&M University, College Station, TX, on "Anti-Idiotypes Mimic Viral Antigens."
5. Immunobiology of Proteins and Peptides, Lake Tahoe, CA, on "Antigen Mimicry by Anti-Idiotypes that Recognize a Cross-Reactive Anti-Hepatitis B Surface Antigen Idiotypes."

Invited Presentations, 1985:

1. Department of Microbiology, University of Texas Health Science Center at San Antonio, on "Anti-idiotypes as Viral Vaccines."
2. International Hybridoma Congress, San Francisco, CA, on "Idiotypic Networks in Hepatitis B Virus Infection."
3. Asian-Pacific Conference on malaria, Honolulu, HI, on "Parasitic Immunity via Idiotypic Strategies."
4. Modern Approaches to Vaccines, 1985, Cold Spring Harbor, NY, on "Anti-Idiotypes as Vaccines for Hepatitis B Virus."
5. Texas Branch of the American Society for Microbiology, San Antonio, TX, Plenary Seminar on "Idiotypic Vaccines Against Infectious Agents."
6. Idiotypic Networks and Immune Regulations, San Antonio, TX, "Experimental Vaccination with Anti-Idiotypic Antibodies."

Invited Presentations, 1986:

1. Johnson and Johnson Biotechnology Center, LaJolla, CA, on "Anti-Idiotypes as Viral Vaccines."
2. Department of Microbiology, University of Texas Health Science Center at San Antonio, "Synthetic Peptides and Anti-idiotypes as Viral Vaccines."
3. Ninth International Congress on Viral and Parasitic Diseases, Munich, Germany, on "Idiotypic Networks in HBV Infection."
4. Modern Approaches to Vaccines 1986, Cold Spring Harbor, NY, on "Synthetic Peptides Identify Neutralizing Epitopes on HIV gp160."
5. Immunologic Intervention Congress, Elmau, Germany, on "New Trends in Vaccines: Idiotypes."
6. Kodak Biotechnology Program, University of Rochester, Rochester, NY, on "The Potential Impact of Anti-idiotypic Antibodies on Biotechnology."
7. Council for the Advancement of Scientific Writers, College Station, TX, on "The Impact of Anti-idiotypes in Biology and Medicine."
8. IDEC Pharmaceuticals, LaJolla, CA, on "The Advancement of Anti-Idiotypic Antibodies as Immunologic Reagents."
9. American Veterinarian Assoc., Chicago, IL, on "Anti-Idiotypic Antibodies: A New Generation of Vaccines."
10. Department of Biology, St. Mary's University, San Antonio, TX, on "Novel Strategies for Vaccine Development."

Invited Presentations, 1987:

1. New York State Department of Health, Albany, NY, on "Potential Vaccines for Controlling HIV Infections."
2. Ortho Pharmaceuticals, Rariton, NJ, on "Anti-Idiotypes Mimic Cellular Receptors and Bind Viral Sites of Interaction."
3. International DNA-Hybridoma Congress, San Francisco, CA, on "Anti-Idiotypes as Vaccines."
4. IDEC Pharmaceuticals, LaJolla, CA, on "Anti-Idiotypic Antibodies as Active Immunotherapeutic Strategies for Treating Chronic Infections."
5. National Institute of Allergy and Infectious Diseases Workshop on AIDS Vaccines, Bethesda, MD, on "Anti-Idiotypes as Vaccines."
6. Departments of Microbiology and Medicine, Westmead Hospital, Sydney, Australia, on "Two Approaches for Idiotypic Based Vaccines Against HIV."
7. International Congress on Biotechnology Applications, Rome, Italy, on "Synthetic Peptides and Anti-Idiotypes for Controlling HIV Infection."
8. Division of Infectious Diseases, Department of Medicine, Catholic University, Rome, Italy, on "Regulating the Immune Response to Viral Antigens."
9. Eli Lilly Company, Indianapolis, IN, on "Utilizing Synthetic Peptides to Define Epitopes on HIV-1 gp160."
10. Third International Conference on AIDS, Washington, D.C., on "Monoclonal Anti-CD4 Induce Homobodies that Mimic CD4 and Bind HIV."
11. Amgen Co., Thousand Oaks, CA, on "Anti-Idiotypic Based Viral Vaccines."
12. Becton Dickinson Monoclonal Center, Mountain View, CA, on "Therapeutic Potential of Monoclonal Anti-CD4 for Treating AIDS."
13. Hepadnaviruses, Cold Spring Harbor, NY, on "Regulating Aspects of Idiotypic Networks on the Immune Response to Hepatitis B Surface Antigen."
14. National Cancer Institute Workshop on AIDS Vaccine, Bethesda, MD, on "Two Aspects of Idiotypic Based Strategies for AIDS."
15. Medical Research Council-Imperial Cancer Research Fund Symposium on AIDS, Royal College of Physicians, London, England, on "Active Immunization Strategies for HIV-1 Infection."
16. IGEN, Rockville, MD, on "Dissecting Humoral Immune Responses Using Synthetic Peptides and Idiotypic Based Reagents."
17. Sandoz Research Institute Symposium on Monoclonal Antibody Immunotherapy, Vienna, Austria, on "Monoclonal Anti-CD4 Immunotherapeutic Strategies for Controlling HIV Infection."

Invited Presentations, 1988:

1. UCLA Symposium on Molecular Basis of Vaccines, Park City, UT, on "Anti-Idiotypic Antibodies as Viral Vaccines."
2. UCLA Symposium on Idiotypic Networks, Los Angeles, CA, on "Idiotypic Networks for Modulating Hepatitis B Virus Infection."

Invited Presentations, 1988: (continued)

3. University of California, San Diego, Symposium on Viral Vaccines, on "Retroviral Vaccines."
4. National Cancer Institute Workshop on HIV Infection, Bethesda, MD, on "Idiotypic Based Vaccine for Controlling HIV."
5. Department of Tropical Medicine and Medical Microbiology, University of Hawaii, Honolulu, HI, on "Synthetic Peptides and Anti-Idiotypes for Controlling HIV Infection."
6. National Institute of Allergy and Infectious Diseases Workshop on AIDS, Bethesda, MD, on "Anti-Idiotypes for Modulating HIV Infection."
7. Fourth International Conference on AIDS, Stockholm, Sweden, on "Therapeutic Strategies Against HIV: Monoclonal Antibody Therapy and Anti-Idiotypic Vaccines."
8. Federation of the American Society of Experimental Biology/American Association of Immunologists Workshop on Confronting AIDS, Las Vegas, NV, on "Nonhuman Primate Species and Their Role in Developing a Vaccine Against HIV."
9. IDEC Pharmaceutical Workshop on Strategies to Control AIDS, LaJolla, CA, on "Two Approaches of Idiotypic Strategies for an HIV Vaccine."
10. Advances in Biotechnology, University of Alabama, Birmingham, on "Anti-Idiotypes as Surrogates for Hepatitis B and Human Immunodeficiency Virus Antigens."
11. National Cooperative Vaccine Development Groups (NCVDG) on AIDS, Virginia Beach, VA, on "Idiotypic Based Strategies for Controlling HIV."
12. American Society of Medical Technologists, San Antonio, TX, on "Use of Anti-Idiotypes in Clinical Medicine."
13. National Cooperative Drug Recovery Group on AIDS, Oakland, CA, on "Intervention Strategies Using Anti-Idiotypes."
14. Argonne National Laboratories, Argonne, IL, on "Idiotypic Cascades Modulate the Immune Response to Viral Antigens."
15. Department of Virology and Epidemiology, Baylor College of Medicine, Houston, TX, on "Idiotypic Based Strategies for Controlling Viral Infections."
16. Research Centers in Minority Institutions and the Asian Pacific Academic Consortium for Public Health, Honolulu, HI, on "Idiotypic Approaches to Developing HIV Vaccine and Therapeutics."

Invited Presentations, 1989:

1. Idiotypes in Biology and Medicine, Gneep, Netherlands, on "Anti-Idiotypes as Viral Vaccines."
2. Fifth Annual Clinical Virology Symposium, Tampa, FL, on "Synthetic Peptides as Diagnostic Tools for HIV Infection."
3. Canadian Society for Microbiology, Laval, (Quebec) Canada, on "Idiotypic Based Vaccine Strategies."
4. Laboratory of Tumor and Cell Biology, NCI, Bethesda, MD, on "Idiotypic and Epitope Specificities of Murine Monoclonal Anti-CD4."
5. Walter Reed Army Institute of Research Symposium on AIDS, Washington, D.C., on "Synthetic Peptides and Anti-Idiotypes for Controlling HIV Infection."
6. Second Annual International Meeting on AIDS Vaccines (National Cooperative Vaccine Development Group), Ft. Lauderdale, FL, on "Idiotypic Strategies Utilizing Monoclonal Anti-Receptor Antibodies."
7. Department of Biology, Trinity University, San Antonio, TX, on "HIV Infection and AIDS."
8. Division of Infectious Diseases, Department of Medicine, Wilford Hall, USAF Medical Center, Lackland, TX, on "Strategies to Control HIV Infection."

Invited Presentations, 1990:

1. Molecular Vaccine Inc., Gaithersburg, MD, on "Anti-Idiotypic Vaccines."
2. Division of Research and Development, Boehringer-Mannheim, Indianapolis, IN, on "HIV in the Workplace."
3. Indiana Corporation for Science and Technology, Indianapolis, IN, on "Applications of Idiotypic Strategies in Biotechnology."
4. Department of Microbiology, Indiana University School of Medicine, on "Vaccine Strategies for HIV."
5. Department of Veterinary Microbiology and Immunology, Purdue University School of Veterinary Medicine on "Anti-Idiotypes as Viral Vaccines."
6. Integrated Biotechnology Corporation, Carmel, IN, on "Idiotypes in Biology and Medicine."
7. IVth International Conference on Retrovirology, Maui, HI, on "Fine Specificity of the Humoral Immune Response to HIV."

Invited Presentations, 1990: (continued)

8. Department of Microbiology, University of Pennsylvania, Philadelphia, PA, on "Functional Duality of Immunoglobulin Variable Regions."
9. Department of Microbiology, University of Oklahoma Health Science Center, on "Idiotypic Based Strategies for Controlling Viral Diseases."
10. Tanox Biosystems, Houston, TX, on "Anti-Idiotypes as AIDS Vaccines."
11. Department of Veterinary Microbiology and Immunology, Cornell University School of Veterinary Medicine, on "Dissecting the Function of Immunoglobulin Variable Regions."
12. Laboratory of Tumor and Cell Biology, NCI, Bethesda, MD, on "Idiotypic Strategies for Controlling HIV."
13. Advances in Dermatology, University of California, San Diego, on "Immunization Against Retroviruses: Current Status and Prospects."
14. Walter Reed Army Institute for Research, Washington, D.C., on "Anti-Idiotypes and Synthetic Peptides for Controlling HIV Infection."
15. Third Annual International Meeting on AIDS Vaccines (National Cooperative Vaccine Development Group), Clearwater Beach, FL, on "Humoral Immunity of HIV."
16. Department of Molecular Genetics and Biochemistry, University of Pittsburgh School of Medicine, on "The Structural Basis of Idiotypes."

Invited Presentations, 1991:

1. Department of Microbiology, Mt. Sinai School of Medicine, New York, on "The Functional Duality of Immunoglobulin Variable Regions."
2. Department of Biology, University of Iowa, Iowa City, IA, on "Antibody Based Vaccine Strategies for HIV."
3. Department of Biochemistry and Molecular Biology, University of Oklahoma Health Science Center, Oklahoma City, OK, on "Molecular and Structural Basis of Antibody Variable Regions and Their Role as Putative Vaccines."
4. Progenics HIV Symposium, Harriman Conference Center, Columbia University, New York.
5. VIIth International AIDS Conference, Florence, Italy, on "Induction of Anti-HIV Antibodies by Immunization with Monoclonal Anti-Idiotypes."
6. Laboratory of Tumor and Cell Biology, NCI, Bethesda, MD, on "Anti-Idiotypes Induce Anti-HIV gp160 Responses."
7. Medicine in Mexico, Hispanic Medical Society, San Antonio, TX, on "Use of Nonhuman Primates in Biomedical Research."
8. International Conference on Autoimmunity, Cancer and AIDS, Mexico City, Mexico, on "Idiotypic Based Vaccine Strategies for Controlling HIV Infection."
9. Marcel Merieux Foundation, Sixth Cent Gardes Symposium on Retroviruses of Human AIDS and Related Animal Diseases, Marnes-la-Coquette, France, on "Humoral Immunity to HIV-1 gp160: Fine Specificity and Anti-Idiotypic Modulation."
10. Department of Immunology, Pasteur Institute, Paris, France, on "Antibody Variable Regions as Antigens."
11. C.W. Johnson Symposium, Current Status of AIDS Research and Health Care, Meharry Medical College, Nashville, TN, on "Fine Specificity of the Humoral Response to HIV-1 gp160 Among Geographically Diverse Populations."

Invited Presentations, 1992:

1. IDEC Pharmaceuticals, LaJolla, CA, on "Humoral immune response to HIV-1 gp610: Epitope Fine Specificity and Idiotypic Analysis."
2. Department of Tropical Medicine and Medical Microbiology, John A. Burns School of Medicine, University of Hawaii, Honolulu, HI, on "Prospects for Developing an HIV Vaccine."
3. Jefferson Cancer Institute, Philadelphia, PA, on "Functional Duality of Murine Monoclonal Anti-CD4."
4. Seminar in Molecular Medicine. University of Texas Institute of Biotechnology, San Antonio, TX, on "Humoral Immunity to HIV-1 gp160 and Interaction with the CD4 Molecule."
5. Henry M. Jackson Foundation, Wilford Hall USAF Medical Center, Lackland AFB, TX, on "Humoral Immunity to HIV-1 gp160 Epitopes as Disease Progression Occurs."
6. Idiotypes and Diseases, Oslo, Norway, on "Anti-Idiotypic Induced Tumor Immunity Against Simian Virus 40 Large Tumor Antigen."
7. Idiotypes and Diseases, Oslo, Norway, on "Structural Basis of a Cross-Reactive Anti-CD4 Idiotypic."
8. Grand Rounds, Department of Medicine, Wilford Hall USAF Medical Center, Lackland AFB, TX, on "Perspectives of Developing a Recombinant AIDS Virus Vaccine."

Invited Presentations, 1992: (continued)

9. Department of Microbiology and Immunology, University of Arizona Health Science Center, Tucson, AZ, on "Immunoglobulin Variable Regions as Antigens: Application to Idiotypic Based Vaccine Strategies."

Invited Presentations, 1993:

1. Oregon Regional Primate Center, Portland, OR, on "Immunoglobulin Variable Region Functional Duality."
2. Department of Biology, Reed College, Portland, OR, on "Developing an HIV-1 Vaccine."
3. John A. Burns School of Medicine, University of Hawaii, on "HIV Vaccine and Therapeutics."
4. National Education Association Scholars Program, Pearl City, HI, on "The Justification for Higher Education."
5. Department of Biology, Special-Seminar, University of Iowa, Iowa City, IA, on "Cytopathogenic Events Related to CD4 Cell Destruction by HIV."
6. HIV and AIDS Symposium, Kumamoto, Japan, on "HIV Infection and AIDS: A Research Perspective."
7. Kumamoto City Hospital, Kumamoto, Japan, on "Prospects for Developing an Effective Vaccine for HIV and AIDS."
8. Department of Biology, Cell Motility and Behavior Symposium, University of Iowa, Iowa City, IA, on "Motility and Behavioral Changes in HIV Induced Syncytium."
9. Division of Microbiology and Infectious Diseases, NIAID, Bethesda, MD, Maternal Immunization Group, on "Maternal Vaccination Using Nonhuman Primate Models."
10. Sixth Annual National Cooperative Vaccine Development Group (NCVDG) for AIDS, Alexandria, VA, Discussant on Panel for "Vaccine Design and Evaluation in Primates."
11. General Electric – EPA Symposium – Immunotoxicity of PCB's, Cincinnati, OH, on "Nonhuman Primate Species to Evaluate the Immunosuppressive Effects of Environmental Toxins."

Invited Presentations, 1994:

1. Meningococcal B Vaccine Workshop, National Institutes of Health (NIAID), Bethesda, MD, on "Nonhuman Primates to Evaluate the Immunogenicity of Vaccine Candidates."
2. International Business Conferences, 2nd Annual Vaccine Strategies Conference, Washington, D.C., on "Immunoglobulin Variable Regions as Vaccines."
3. Department of Virology, Animal Diseases Research Institute, Ottawa – Nepean, Canada, on "Immunoglobulin Variable Region Structure-Function Analysis."
4. Division of Life Sciences, University of Texas in San Antonio, San Antonio, TX, on "Protein Structure-Function Analysis: Immunoglobulin Variable Region Functional Duality."
5. International Congress on the Immunoglobulin Gene Superfamily-Structure and Function, Idiotypes and Diseases, Conference, Maui, HI, on "Dissecting Immunoglobulin Variable Region Function."
6. International Business Conferences, Novel Vaccine Strategies Conference, Bethesda, MD, on "Overview of Idiotypic-Based Vaccine Strategies for HIV."
7. Department of Microbiology and Immunology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, on "Fine Specificity of the Humoral Immune Response to HIV-1 gp160 among Geographically Diverse Populations."
8. International Exchange Center, Kumamoto City, Japan, Keynote Speaker, on "Education as a Vaccine Strategy for AIDS."
9. Kumamoto city Hospital, Kumamoto City, Japan, on "Geographic Diversity of HIV Infection."
10. Department of Molecular and Cellular Biology, University of Connecticut, Storrs, CT, on "Structure and Function Analysis of Monoclonal Anti-CD4: A Potential Post-Exposure Therapy for HIV Infection."
11. Center for Biotechnology, University of Connecticut, Storrs, CT, on "Biotechnology in the University: Current Status and Future Vision."
12. Seventh Annual National Cooperative Vaccine Development Group (NCVDG) for AIDS, Reston, VA, Discussant in Workshop on "Nonhuman Primate Models."
13. Eastern Pennsylvania Branch of the American Society for Microbiology, Vaccines: Preventative Strategies for the 21st Century, Philadelphia, PA, on "Progress of Idiotypic Based Vaccine Strategies for Infectious Diseases and Cancer."

Invited Presentations, 1995:

1. Division of Infectious Diseases, Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, on "Nonhuman Primate Models for Infectious Diseases."

Invited Presentations, 1995: (continued)

2. Program on Toxicology, College of Pharmacy, University of Oklahoma Health Sciences Center, Oklahoma City, OK, on "Nonhuman Primate Models and In Vitro Immunologic Assays: Potential Applications in Pharmacology."
3. International Business Conferences, Gene Therapy and Nucleic Acid Vaccination Strategies, Bethesda, MD, on "Viral Induced Naked DNA Tumor Vaccines: A Comparison Between Nucleic Acid and Recombinant Subunit Vaccine Strategies."
4. New York Academy of Sciences, DNA Vaccines: A New Era in Vaccinology, Crystal City, VA, on "Protection Against a Lethal Tumor Challenge by DNA Vaccination."
5. Keynote Address, Graduate Education Research Day, University of Oklahoma Health Sciences Center, Oklahoma City, OK, on "From Jenner to Jerne: New Approaches to Vaccines."
6. American Society for Virology, Austin, TX, on "Viral induced naked DNA tumor vaccines: a comparison between nucleic acid and recombinant subunit vaccine strategies."
7. American Society for Virology, Austin, TX, on "Examination of lymphokines induced in mice following immunization with recombinant simian virus 40 large tumor antigen."
8. Clinical Immunology Society, International Union of Immunological Societies, San Francisco, CA, on "DNA vaccine strategies and immune mechanisms to control viral induced tumors."
9. Free Radical and Aging Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, on "The Utility of Nonhuman Primates in Biomedical Research."
10. American Chemical Society, Conference on Formulations and Drug Delivery, Boston, MA, on "Nucleic Acid vaccination against viral induced tumors and comparison to other vaccine strategies."
11. Department of Biochemistry and Molecular Biology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, on "Functional duality of immunoglobulin variable regions."
12. Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, on "DNA vaccines against infectious diseases and cancer."
13. Department of Molecular Biology, Paterson Institute for Cancer Research, Christie Hospital, Manchester, United Kingdom, on "DNA vaccines against SV40 induced tumors."
14. International Conference on Therapies for Viral Hepatitis, Kauai, HI, on "Molecular and structural characterization of antibodies to hepatitis B surface antigen that recognize a protective epitope."

Invited Presentations, 1996:

1. International Exchange Center, Kumamoto City, Japan, Keynote Speaker for Fiftieth Anniversary Ceremony of Kumamoto City Hospital, on "The Global Impact of HIV Infection and AIDS."
2. International Meeting on Nucleic Acid Vaccines for the Prevention of Infectious Diseases (W.H.O. and NIH joint meeting), Bethesda, MD, on "Nonhuman Primate Models to Evaluate Nucleic Acid Vaccines."
3. Department of Biological Sciences, University of Tulsa, Tulsa, OK, on "DNA Vaccines against Infectious Diseases and Cancer."
4. Department of Microbiology, University of Tennessee, Knoxville, TN, on "AIDS, Nonhuman Primate Models, and DNA Vaccines: A Synthesis."
5. Department of Biological Sciences, Southwestern Oklahoma State University, Weatherford, OK, on "DNA as a New Approach to Vaccines."
6. International Business Conferences, Genetic Vaccines and Immunotherapeutic Strategies, Washington, D.C., on "Genetic Vaccination against Simian Virus 40 induced Tumors."

Invited Presentations, 1997:

1. Gastroenterology Research Conference, Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, on "Hepatitis G Virus."
2. Oklahoma Gut Club, Oklahoma City, OK, on "Hepatitis G Virus."
3. Oklahoma Center for Neuroscience, Update in Neurology 1997, Oklahoma City, OK, on "Immunologic Mechanisms for Prophylactic and Therapeutic Treatment Strategies."
4. Universidad de Autonoma Guadalajara, Guadalajara, Mexico, on "HIV and AIDS."
5. Department of Biological Sciences, University of Iowa, Iowa City, IA, on "Vaccination Strategies employing DNA."
6. Harvard AIDS Institute Conference on HIV Vaccines for Developing Countries, MIT Endicott House, MA, on "Delivery Systems for HIV Vaccine Candidates."
7. Gordon Research Conference on Genetic Vaccines, Plymouth State College, NH, on "Genetic Immunization and Immune Response in Simian Virus 40 Tumorigenic Models."

Invited Presentations, 1997: (continued)

8. Molecular Pathology Conference, University of Oklahoma Health Sciences Center, Oklahoma City, OK, on "A New Concept in Vaccine Development: Genetic Vaccination/DNA Vaccines."
9. Nextran Inc., Princeton, NJ, on "Nonhuman primate models and their role in xenotransplantation."
10. International Business Communications 3rd Annual Genetic Vaccines Conference, Orlando, FL, on "DNA Based Cancer Vaccines."
11. Merck, Sharpe & Dohme, West Point, PA, on "Structure, function and neutralizing capacities of monoclonal antibodies to hepatitis B surface antigen."

Invited Presentations, 1998:

1. Oklahoma Medical Research Foundation NIH Science Forum, Oklahoma City, OK, on "Concepts related to the development of vaccines for HIV."
2. IXth International Congress of Parasitology, Makuhari, Chiba, Japan, on "Concepts of DNA vaccination strategies against parasitic infections."
3. Department of Immunology and Parasitology, Tokushima University, Tokushima, Japan, on "Comparison of tumor vaccination strategies against SV40 induced tumors."
4. Laboratory Animal Workshop, University of Oklahoma Health Sciences Center, Oklahoma City, OK, on "In vitro production of monoclonal antibodies – The pros and cons."
5. Commission of the European Union, European Co-operation in Scientific and Technology Research Annual Workshop on Vaccines against animal coccidiosis, Toledo, Spain, on "DNA vaccines and the induction of protective immunity."
6. St. Georges Hospital, London, United Kingdom, on "Cancer vaccination strategies."
7. Novovax Inc., Rockville, MD, on "Nonhuman primates to evaluate vaccine immunogenicity."
8. RIMSA Pharmaceutical and the University D'Autonoma Guadalajara Medical School, Guadalajara, Mexico, on "Anti-CD4 as inhibitors of HIV infection."

Invited Presentations, 1999:

1. National Center for Research Resources Program Directors Meeting, Miami, FL, on "Developing a baboon research resource."
2. Alliance Pharmaceutical, San Diego, CA, on "The infant baboon model for vaccine immunogenicity."
3. The University of Tennessee Medical Center at Knoxville, Knoxville, TN, on "Concepts and principles involved in HIV vaccine development: Failure and disappointment may lead to success."
4. Congressional Committee on Government Reform, Washington, D.C., on "Vaccine Safety and Public Policy Issues."
5. Tulane University Medical Center, New Orleans, LA, on "Non-Human Primates and Their Role in Immunologic Investigation."
6. Development and Clinical Progress of DNA Vaccines, Langen, Germany, on "DNA Cancer Vaccination Strategies Target SV40 Large Tumor Antigen in Experimental Metastasis."
7. International Conference on Therapies for Viral Hepatitis, Maui, HI, on "Fetal Vaccination with Hepatitis B Surface Antigen and Characterization of the Maternal and Fetal Immune Response."

Invited Presentations, 2000:

1. American Association for Cancer Research, 91st Annual Meeting, San Francisco, CA, on "Oncoprotein based cancer vaccination strategies and comparison of immunity in murine tumor models."
2. National Center for Research Resources, Manassas, VA, Annual Comparative Medicine Resource Director's Meeting, Manassas, VA.
3. American Association of Immunologists and Clinical Immunology Society Joint Annual Meeting, Immunology 2000, Seattle, WA, on "CD4+ T Helper Cells and Antibody are Required for Rejection of Tumors in a Murine Experimental Metastasis Model."
4. Tulane Regional Primate Research Center, Covington, LA, on "Fetal Vaccination Strategies in Nonhuman Primates."
5. Department of Microbiology, Texas Tech University Health Sciences Center, Lubbock, TX, on "Antibody Based Mechanisms in Tumor Immunity."
6. National Institute of Allergy and Infectious Diseases Workshop. "The Developing Immune System: Gaps in Knowledge," Arlington, VA, on "Nonhuman Primate Models for the Developing Fetal Immune Response."

Invited Presentations, 2000: (continued)

7. National Vaccine Information Center. "Second International Public Conference on Vaccination "Science for Hope and Healing: Challenge the Status Quo," Arlington, VA, on "Hepatitis B Vaccine and Correlates of Immunity."
8. Geron Corporation, San Francisco, CA, "Telomerase Vaccination Project Team Focus Meeting" on "DNA Vaccination Strategies Against Cancer."
9. Novavax Inc., Rockville, MD, "Scientific Advisory Board Meeting" on "DNA Vaccines Against Infectious Agents."
10. Annual Meeting of the Midwest Section American Federation for Medical Research, Chicago, IL, on "Potential of DNA Vaccines in Controlling Infectious Diseases and Cancer."

Invited Presentations, 2001:

1. Update in Neurology, Department of Neurology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, on "Immune Responses and Autoimmune Disease."
2. Department of Biological Sciences, Texas Tech University, Lubbock, TX, on "SV40 Large Tumor Antigen Cancer Vaccines and Mechanisms of Tumor Immunity."
3. Department of Pediatrics, Texas Tech University School of Medicine, Lubbock, TX. on "Concepts of Neonatal Immunity and Effects on Vaccination."
4. Texas Tech University Health Sciences Center, Lubbock, TX. on "Anthrax."
5. Immunization Safety Review Committee, Institute of Medicine/National Academy of Sciences, Seattle, WA, on "In Utero Exposure and its Effects on the Developing Immune Response."
6. HEP DART 2001, Frontiers in Drug Development for Viral Hepatitis, Maui, HI, on "The Neonates Developing Immune Response to Hepatitis B Surface Antigen and the Effects of Preexisting Maternal and Fetal Immunity."

Invited Presentations, 2002:

1. International Congress On Lung Cancer, Kona, HI, on "Murine Experimental Pulmonary Metastasis Models for Immunotherapy Modalities Relevant to Mesothelioma."
2. Department of Physiology, Texas Tech University Health Sciences Center, Lubbock, TX. On "Cancer Vaccination Strategies and Immunologic Mechanisms of Tumor Immunity Employing a Viral Encoded Tumor Specific Antigen."

Invited Presentations, 2003:

1. International Congress on Lung Cancer, Marbella, Spain, on "Cancer Vaccination Strategies to Prevent Experimental Pulmonary Metastasis in Murine Models."
2. American Society for Clinical Oncology meeting on Lung Cancer, Wailea, HI, on "Mechanisms of Tumor Antigen Based Vaccination Strategies for Preventing Murine Experimental Pulmonary Metastasis."
3. Wolf-Greenfield and Associates, Boston, MA, on "Monoclonal Antibody Therapy for Treating Cancer."

Community Service Lectures:

1. Hispanic Association of Colleges and Universities, EXCEL Program, on "Confronting AIDS," San Antonio, TX.
2. San Antonio Home Nurses Association, on "HIV Infection in the Workplace," San Antonio, TX.
3. Northside Independent School District, Gifted and Talented Program, on "Creative Thinking in Research," San Antonio, TX.
4. Conopus Club, on "New Strategies for Treating AIDS," San Antonio, TX.
5. Taft High School, National Honor Society Induction, on "A Comparison of Higher Education to the Life Cycle of a Virus," San Antonio, TX.
6. Fox Tech High School, English and Biology Classes, on "The Important of Education in Enhancing Career Opportunities," San Antonio, TX.
7. Oak Hills Rotary Club, on "HIV and AIDS, Facts and Fiction," San Antonio, TX.
8. John Marshall High School, Mu Alpha Theta Induction, on "The Role of Biomedical Research in the 21st Century," San Antonio, TX.

Community Service Lectures: (continued)

9. Our Lady of the Lake University, EXCEL Program, on "Prerequisites of Higher Education for Career Opportunities," San Antonio, TX.
10. American Cancer Society, San Antonio Metro Unit, on "Idiotype Strategies to Treat Cancer," San Antonio, TX.
11. Oaks Club, on "Update on HIV Vaccines," San Antonio, TX.
12. Kiwanis Club of Greater Randolph Area, on "An Overview of HIV Infection," Universal City, TX.
13. Texas Insurance Underwriters Association, on "The Role of Insurance Companies in Retroviral Infections," Austin, TX.
14. Palo Alto Elementary School, on "The Truths on HIV Infection and AIDS," San Antonio Independent School District, San Antonio, TX.
15. Federal Bureau of Investigation, South Texas, on "HIV and HBV as Threats to Investigating Agents," San Antonio, TX.
16. Alamo Area Home Health Care, on "An Update on AIDS Vaccines," San Antonio, TX.
17. Texas Education Association, South Texas, on "HIV Education Vaccines," San Antonio, TX.
18. San Antonio Wedge Workshop, Edison High School, on "HIV and AIDS," San Antonio, TX.
19. Mark Twain Middle School, on "HIV Infection and AIDS," San Antonio Independent School District, San Antonio, TX.
20. Kiwanis Club of Downtown San Antonio, on "HIV and AIDS," San Antonio, TX.
21. San Antonio City Council, on "The Prospects for Developing a Cure for AIDS," San Antonio, TX.
22. San Antonio Winners High School, on "HIV Infection and AIDS," San Antonio, TX.
23. Stewart Elementary School, on "HIV and AIDS, The Seeds of Change," San Antonio Independent School District, San Antonio, TX.
24. Judson High School, on "Myths and Facts About HIV and AIDS," Judson Independent School District, Converse, TX.
25. Northside Independent School District, San Antonio Wedge Workshop, on "HIV and AIDS," San Antonio, TX.
26. Oak Hills Terrace Elementary School, on "AIDS is No Game," Northside Independent School District, San Antonio, TX.
27. San Antonio City Council, on "HIV Infection: A Perspective on Vaccine and Therapeutic Development," San Antonio, TX.
28. Texas Education Association – South Texas, on "An HIV Education Vaccine," San Antonio, TX.
29. City Public Service Scholars Program, "HIV Infection and AIDS: A Research Perspective," San Antonio, TX.
30. Randolph Field Area Rotary Club, on "HIV Infection and AIDS," Universal City, TX.
31. Institutional Service, Department of Education, State of Hawaii, on "Developing an HIV Educational Vaccine for Adolescents."
32. Kiwanis Club of Greater Randolph Area, on "Current State of HIV Research," Universal City, TX.
33. TI-IN Network, on "AIDS: Battling the Human Immunodeficiency Virus," San Antonio, TX.
34. Alamo Chapter of Credit Unions, on "AIDS in the Workplace," San Antonio, TX.
35. Oklahoma Health Center Foundation, on "Progress on HIV Vaccines and Therapeutics," Oklahoma City, OK.
36. Market Lubbock, on "Biotechnology opportunities," Lubbock, TX.
37. City of Lubbock Chamber of Commerce, on "Establish a National Homeland Security Institute." Lubbock, TX.
38. City of Austin Chamber of Commerce, on "Biotechnology Opportunities in West Texas." Austin, TX.